Form 8-K

Contacts:

For investors:

Robert C. Weiner

For media:

Brian C. Kosoy

Vice President, Investor Relations

Public Relations

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OL+c68Bk2z/qi81dEiwymAt6X2wdGd00ZkM3ma2G43A2rBb8utPmzbs1UPwbMsAW s4QHLfFarck15q2AS8N3LA== 0001193125-08-010606.txt : 20080123 0001193125-08-010606.hdr.sgml : 20080123 20080123170136 ACCESSION NUMBER: 0001193125-08-010606 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20080123 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080123 DATE AS OF CHANGE: 20080123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSS WORLD MEDICAL INC CENTRAL INDEX KEY: 0000920527 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 592280364 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23832 FILM NUMBER: 08545266 BUSINESS ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 BUSINESS PHONE: 9043323000 MAIL ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 FORMER COMPANY: FORMER CONFORMED NAME: PHYSICIAN SALES & SERVICE INC /FL/ DATE OF NAME CHANGE: 19940318 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 23, 2008

PSS WORLD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

Commission File Number: 0-23832

Florida

59-2280364

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification Number)

4345 Southpoint Blvd.

Jacksonville, Florida

32216

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code (904) 332-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Disclosure of Results of Operations and Financial Condition.

On January 23, 2008, PSS World Medical, Inc. (the “Company”) issued a press release in which the Company announced its financial results for the three and nine months ended December 28, 2007. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. In connection with the press release, the Company has also made available certain supplemental financial information (“the Financial Supplement”) for the three and nine months ended December 28, 2007, which may be found on the Company’s website at www.pssd.com. This Financial Supplement is included as Exhibit 99.2 to this report and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information included or incorporated in this report, including Exhibit 99.1 and Exhibit 99.2, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

The press release and Financial Supplement contain financial measures that are not in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company has provided reconciliations within the press release and Financial Supplement of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company provides non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures are intended to supplement the user’s overall understanding of the Company’s current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company’s core operating results or business performance. However, these non-GAAP financial measures are not intended to supercede or replace the Company’s GAAP results. A detailed reconciliation of the GAAP results to the non-GAAP results is provided within the financial supplement.

Item 9.01

Financial Statements and Exhibits.


Exhibit Number		Description
99.1		Press Release dated January 23, 2008 with respect to the Registrant’s financial results for the three and nine months ended December 28, 2007.

99.2		Financial Supplement for the three and nine months ended December 28, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 23, 2008


PSS WORLD MEDICAL, INC.

By:		/s/ David M. Bronson
Name:		David M. Bronson
Title:		Executive Vice President and Chief Financial Officer

EXHIBIT INDEX


99.1		Press Release dated January 23, 2008.

99.2		Financial Supplement for the three and nine months ended December 28, 2007

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

NEWS RELEASE

PSS WORLD MEDICAL REPORTS RESULTS

FOR FISCAL 2008 THIRD QUARTER

Fiscal 2008 Third Quarter Highlights:

•

Consolidated net sales growth of 1.5% (9.4% excluding last fiscal year flu sales)

•

Physician Business net sales declined by 0.8% (10.4 % growth excluding last fiscal year’s flu sales)

•

Elder Care Business net sales growth of 7.3%

•

Consolidated earnings per diluted share increased 38% to $0.22 (Net loss on flu of $0.03 per diluted share included in last fiscal year’s third quarter)

•

Operating margin of 7.3% for Physician Business and 4.7% for Elder Care Business

•

Consolidated cash flow from operations of $13.3 million

•

Repurchased approximately 700,000 shares for $13.1 million

•

Agreement finalized with the State of Florida with approximately $1.4 million of additional pedigree-related costs in the third quarter

Jacksonville, Florida (January 23, 2008) – PSS World Medical, Inc. (NASDAQ GS:PSSI) announced today its results for the fiscal 2008 third quarter and nine months ended December 28, 2007.

David A. Smith, Chairman and Chief Executive Officer, commented, “Both businesses grew at two times their respective markets’ growth rate with solid operating results and profit growth. Our business model continues to drive increased operating efficiencies, more than offsetting an environment of rising costs. Our customer programs and solutions continue to improve cash flow and efficiency, alleviating the pressures on customer income. We are excited to begin improving pharmaceutical-related services for our Florida-based customers over the next 90–120 days.”

“We expect to have a strong finish to this fiscal year, the final year of our three-year strategic plan, and accomplish our goal of $0.81-$0.85 earnings per diluted share for fiscal year 2008. The Company is now in the planning phase for the fiscal years 2009- 2011 strategic plan, and we look forward to sharing these plans on May 22 at our annual Investor Day,” concluded Mr. Smith.

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 2

January 23, 2008

Net sales for the three months ended December 28, 2007, were $465.2 million, an increase of 1.5% (9.4% excluding last fiscal year’s flu sales), compared with net sales of $458.4 million for the three months ended December 29, 2006. Net sales for the three months ended December 28, 2007, for the Physician Business decreased by 0.8% (10.4% growth excluding last fiscal year’s flu sales), while net sales for the Elder Care Business increased by 7.3%. Income from operations for the three months ended December 28, 2007, was $24.1 million compared with income from operations for the three months ended December 29, 2006, of $17.9 million. Net income for the three months ended December 28, 2007, was $14.2 million, or $0.22 per diluted share, compared with net income for the three months ended December 29, 2006, of $11.1 million, or $0.16 per diluted share.

Net sales for the nine months ended December 28, 2007, were $1.4 billion, an increase of 4.9% (9.0% excluding last year flu sales), compared with net sales of $1.3 billion for the nine months ended December 29, 2006. Net sales for the nine months ended December 28, 2007, for the Physician Business increased by 4.2% (10.1% excluding last fiscal year’s flu sales), while net sales for the Elder Care Business increased by 6.5%. Income from operations for the nine months ended December 28, 2007, was $63.1 million compared with income from operations for the nine months ended December 29, 2006, of $58.2 million. Net income for the nine months ended December 28, 2007, was $37.3 million, or $0.56 per diluted share, compared with net income for the nine months ended December 29, 2006, of $34.8 million, or $0.50 per diluted share.

David M. Bronson, Executive Vice President and Chief Financial Officer, commented, “We continue to see positive traction in our key business strategies, with solid growth in pharmaceutical, equipment and private label sales. Operating margins continued to improve in both businesses, even with increased costs in the quarter related to pedigree compliance. Despite strong revenue growth, we continued to generate cash from operations, which allowed the continuation of our share repurchase program. Over the last three quarters, share repurchases have been an accretive use of capital, adding about $0.01 to our reported earnings per diluted share.”

Separately, the Company noted that it has resolved outstanding issues with the Florida Department of Health regarding compliance with new state pharmaceutical pedigree regulations. In fiscal year 2008, costs associated with pedigree law compliance and settlement with the Florida Department of Health were $2.7 million, or $0.03 per diluted share, for the first quarter, $ 2.1 million, or $0.02 per diluted share, for the second quarter, and $1.4 million, or $0.01 per diluted share, in the third quarter.

The agreement resolves issues regarding interpretation of procedures for documenting the ordering, receipt, storage, and shipping of certain products covered by Florida drug pedigree legislation. Products covered by this action include prescription pharmaceutical products used by physicians in their practices, such as vaccines, ointments and creams, anesthetics, and topicals used in office procedures. The Company expects to resume sales and shipments of these products from its Florida distribution operations over the next 90—120 days. The Company also reiterated its commitment to full compliance with the spirit and intent of pedigree legislation and will continue to work with state regulators to ensure compliance with these new regulations.

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 3

January 23, 2008

The Company has today filed with the SEC a Form 8-K that includes a copy of this press release and its related Fiscal 2008 Third Quarter Financial Workbook, which contains GAAP and non-GAAP financial measures, and is available on the Company’s website, www.pssworldmedical.com.

A listen-only simulcast as well as a 90-day online replay of PSS World Medical’s fiscal 2008 third quarter conference call can be found in the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations,” or at www.opencompany.info, on January 24, 2008, beginning at 8:30 a.m. Eastern time.

PSS World Medical, Inc. is a national distributor of medical products to physicians and elder care providers through its two business units. Since its inception in 1983, PSS has become a leader in the two market segments that it serves with a focused market approach to customer services, a consultative sales force, strategic acquisitions, strong arrangements with product manufacturers and a unique culture of performance.

Additional financial information pertaining to PSS World Medical financial results may be found by visiting the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations.” If you should need assistance accessing the information, please call Investor Relations at 904-332-3000.

All statements in this release that are not historical facts, including, but not limited to, statements regarding anticipated growth in revenue, gross and operating margins, and earnings, statements regarding the Company’s current business strategy, the Company’s ability to complete and integrate acquired businesses and generate acceptable rates of return, the Company’s projected sources and uses of cash, and the Company’s plans for future development and operations, are based upon current expectations. Specifically, forward-looking statements in this Press Release include, without limitation, the Company’s expected results in GAAP EPS for the consolidated company; the expected operational cash flow in fiscal year 2008 and the Company’s expectation that it will continue to be in compliance with Florida pedigree regulations and other state pedigree regulations. These statements are forward-looking in nature and involve a number of risks and uncertainties. Actual results may differ materially. Among the factors that could cause results to differ materially are the following: pricing and customer credit quality pressures; the loss of any of our distributorship agreements and our reliance on relationships with our suppliers and vendors; our reliance on a limited number of chain business elder care customers; the availability of sufficient capital to finance the Company’s business plans on terms satisfactory to the Company; lower revenue and earnings that may result from competition; the ability of the Company to adequately defend or reach a settlement on outstanding litigation matters and investigations involving the Company or its management; changes in labor, equipment and capital costs; changes in legislation and regulations affecting the Company’s business, such as the Medicare cliffs, changes in malpractice insurance rates and tort reform; future acquisitions or strategic partnerships; general business, competitive and economic factors and conditions; and other factors described from time to time in the Company’s reports filed with the Securities and Exchange Commission. Many of these

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 4

January 23, 2008

factors are outside the control of the Company. The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company also wishes to caution readers that it undertakes no duty or is under no obligation to update or revise any forward-looking statements.

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 5

January 23, 2008

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Operations

(In millions, except per share and share data)


	Three Months Ended						Nine Months Ended
	Dec. 28, 2007			Dec. 29, 2006			Dec. 28, 2007			Dec. 29, 2006
	Dec. 28, 2007			Dec. 29, 2006			Dec. 28, 2007			Dec. 29, 2006
Net sales	$	465.2		$	458.4		$	1,362.0		$	1,298.6
Cost of goods sold		330.2			335.2			966.8			931.6

Gross profit		135.0			123.2			395.2			367.0
General and administrative expenses		79.4			75.2			240.3			222.3
Selling expenses		31.5			30.1			91.8			86.5

Income from operations		24.1			17.9			63.1			58.2

Other (expense) income:
Interest expense		(1.8	)		(1.3	)		(4.7	)		(4.1	)
Interest and investment income		—			0.4			0.7			0.8
Other income		0.9			0.5			1.9			1.4

		(0.9	)		(0.4	)		(2.1	)		(1.9	)

Income before provision for income taxes		23.2			17.5			61.0			56.3
Provision for income taxes		9.0			6.4			23.7			21.5

Net income	$	14.2		$	11.1		$	37.3		$	34.8

Earnings per share – basic	$	0.22		$	0.17		$	0.57		$	0.52

Earnings per share – diluted	$	0.22		$	0.16		$	0.56		$	0.50

Weighted average shares (in thousands):
Basic		63,999			67,054			65,533			67,272
Diluted		65,756			69,458			67,195			69,294

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 6

January 23, 2008

PSS WORLD MEDICAL, INC.

Condensed Consolidated Balance Sheets

(In millions, except per share and share data)


	Dec. 28, 2007		March 30, 2007
	Dec. 28, 2007		March 30, 2007
	*(Unaudited)*
ASSETS
Current Assets:
Cash and cash equivalents	$	15.0	$	46.7
Accounts receivable, net		224.3		222.8
Inventories		214.3		174.1
Deferred tax assets, net		9.2		8.8
Prepaid expenses and other		31.6		34.4

Total current assets		494.4		486.8
Property and equipment, net		89.9		88.6
Other Assets:
Goodwill and intangibles, net		138.5		137.1
Investment in available-for-sale securities		50.2		—
Other		68.6		62.5

Total assets	$	841.6	$	775.0

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	161.7	$	131.3
Accrued expenses		34.4		37.2
Revolving line of credit and current portion of long-term debt		33.7		2.2
Other		15.8		11.5

Total current liabilities		245.6		182.2
Long-term debt, excluding current portion		150.8		150.7
Other noncurrent liabilities		67.2		61.2

Total liabilities		463.6		394.1

Shareholders’ Equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized, no shares issued and outstanding		—		—
Common stock, $0.01 par value; 150,000,000 shares authorized, 64,664,200 and 67,179,475 shares issued and outstanding at December 28, 2007, and March 30, 2007, respectively		0.6		0.7
Additional paid-in capital		243.9		300.0
Retained earnings		117.3		80.2
Accumulated other comprehensive income		16.2		—

Total shareholders’ equity		378.0		380.9

Total liabilities and shareholders’ equity	$	841.6	$	775.0

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 7

January 23, 2008

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Cash Flows

(In millions)


	Three Months Ended						Nine Months Ended
	Dec. 28, 2007			Dec. 29, 2006			Dec. 28, 2007			Dec. 29, 2006
Cash Flows from Operating Activities:
Net income	$	14.2		$	11.1		$	37.3		$	34.8
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		4.7			4.2			14.0			12.5
(Benefit) provision for deferred income taxes		0.9			(3.7	)		(1.4	)		4.1
Amortization of intangible assets		1.4			1.5			4.2			4.4
Provision for doubtful accounts		1.7			2.4			3.5			3.4
Non-cash compensation expense		1.2			0.7			3.1			1.5
Amortization of debt issuance costs		0.4			0.4			1.1			1.1
Provision for deferred compensation		(0.5	)		0.9			1.2			1.7
Changes in operating assets and liabilities, net of effects from business combination:
Accounts receivable, net		6.3			3.4			(1.9	)		(14.0	)
Inventories		(26.2	)		(14.1	)		(37.9	)		(12.7	)
Prepaid expenses and other current assets		(6.5	)		7.2			(0.9	)		(1.2	)
Other assets		0.5			(1.7	)		(8.4	)		(1.4	)
Accounts payable		11.9			16.6			25.8			23.1
Accrued expenses and other liabilities		3.3			(1.9	)		6.0			3.6

Net cash provided by operating activities		13.3			27.0			45.7			60.9

Cash Flows from Investing Activities:
Payments for business combinations, net of cash acquired		—			(2.4	)		(15.1	)		(2.5	)
Payments for investment in available-for-sale securities		—			—			(24.1	)		—
Capital expenditures		(4.2	)		(2.8	)		(13.8	)		(10.6	)
Proceeds from note receivable		—			—			2.7			—
Payments on non-solicitation agreements		—			(0.2	)		—			(1.0	)
Other		(0.1	)		—			(0.1	)		—

Net cash used in investing activities		(4.3	)		(5.4	)		(50.4	)		(14.1	)

Cash Flows from Financing Activities:
Net proceeds from revolving line of credit		1.2			—			32.6			—
Proceeds from exercise of stock options		0.6			2.4			2.3			7.3
Excess tax benefits from share-based compensation arrangements		0.5			0.6			1.2			3.2
Proceeds from borrowings		—			0.5			—			1.5
Purchase of common stock		(13.1	)		(15.2	)		(62.5	)		(27.4	)
Payment under capital lease obligations		(0.2	)		(0.2	)		(0.6	)		(0.4	)
Other		—			(0.5	)		—			—

Net cash (used in) provided by financing activities		(11.0	)		(12.4	)		(27.0	)		(15.8	)

Net increase in cash and cash equivalents		(2.0	)		9.2			(31.7	)		31.0
Cash and cash equivalents, beginning of period		17.0			45.7			46.7			23.9

Cash and cash equivalents, end of period	$	15.0		$	54.9		$	15.0		$	54.9

-MORE-

PSSI Reports Results For Fiscal 2008 Third Quarter

Page 8

January 23, 2008

PSS WORLD MEDICAL, INC.

Net Sales Adjustment for Influenza Vaccine Sales

Proforma Net Sales

(In millions)


	For the Three Months Ended						For the Nine Months Ended
	Dec. 28, 2007		Dec. 29, 2006		Growth		Dec. 28, 2007		Dec. 29, 2006		Growth
*Consolidated:*
Net sales	$	465.2	$	458.4	1.5	%	$	1,362.0	$	1,298.6	4.9	%
Influenza vaccine sales		—		33.3				—		48.7

Net sales adjusted for influenza vaccine sales	$	465.2	$	425.1	9.4	%	$	1,362.0	$	1,249.9	9.0	%


*Physician Business:*
Net sales	$	326.5	$	329.2	(0.8	)%	$	952.9	$	914.4	4.2	%
Influenza vaccine sales		—		33.3				—		48.7

Net sales adjusted for influenza vaccine sales	$	326.5	$	295.9	10.4	%	$	952.9	$	865.7	10.1	%

-END-

EX-99.2 3 dex992.htm FINANCIAL SUPPLEMENT FOR THE THREE AND NINE MONTHS ENDED DECEMBER 28, 2007 Financial Supplement for the three and nine months ended December 28, 2007

EXHIBIT 99.2

LOGO

Financial Data Workbook

For the Third Quarter of Fiscal Year 2008 ending December 28, 2007

PSS World Medical, Inc.

As of December 28, 2007

Current Fiscal Year

(in thousands, except per share data)


	Fiscal 2008
	Q1			Q2			Q3
Net Sales	$	438,910		$	457,930		$	465,208
Cost of Goods Sold		311,227			325,390			330,215

Gross Profit		127,683			132,540			134,993
General & Administrative Expenses		83,600			77,315			79,370
Selling Expenses		29,551			30,763			31,509

Income from operations		14,532			24,462			24,115
Interest Expense		(1,358	)		(1,533	)		(1,811	)
Interest & Investment Income		528			114			26
Other Income		544			546			833

Income from Operations before Income Taxes		14,246			23,589			23,163
Provision for Income Taxes		5,559			9,106			9,001

Net Income	$	8,687		$	14,483		$	14,162


Earnings per share - Basic:
Net Income	$	0.13		$	0.22		$	0.22


Earnings per share - Diluted:
Net Income	$	0.13		$	0.22		$	0.22


WASO - Basic		66,793			65,806			63,999
WASO - Diluted		68,765			67,067			65,756

Net Sales by Segment:
Physician Business	$	306,245		$	320,171		$	326,520
Elder Care Business		132,665			137,759			138,688

	$	438,910		$	457,930		$	465,208


Billing Days:		64			63			62

Net Sales Per Billing Day:
Physician Business	$	4,785		$	5,082		$	5,266
Elder Care Business		2,073			2,187			2,237

	$	6,858		$	7,269		$	7,503

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

As of December 28, 2007

(in thousands, except per share data)


	Fiscal 2005															Fiscal 2006															Fiscal 2007
	Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total
Net Sales (1)	$	330,361		$	364,267		$	377,842		$	401,299		$	1,473,769		$	387,129		$	385,819		$	423,781		$	422,688		$	1,619,417		$	413,135		$	427,059		$	458,421		$	443,024		$	1,741,639
Cost of Goods Sold		234,585			258,945			268,675			288,209			1,050,414			276,654			273,512			303,707			298,219			1,152,092			293,233			303,203			335,186			310,007			1,241,629

Gross Profit		95,776			105,322			109,167			113,090			423,355			110,475			112,307			120,074			124,469			467,325			119,902			123,856			123,235			133,017			500,010
General & Administrative Expenses (2)		60,948			64,300			68,827			68,130			262,205			70,337			69,279			72,053			75,639			287,308			73,664			73,391			75,222			78,423			300,700
Selling Expenses		23,453			24,625			25,082			26,431			99,591			25,774			26,217			27,469			28,148			107,608			27,498			28,878			30,140			30,307			116,823

Income from operations		11,375			16,397			15,258			18,529			61,559			14,364			16,811			20,552			20,682			72,409			18,740			21,587			17,873			24,287			82,487
Interest Expense		(1,942	)		(1,817	)		(1,737	)		(1,360	)		(6,856	)		(1,509	)		(1,358	)		(1,561	)		(1,456	)		(5,884	)		(1,406	)		(1,336	)		(1,320	)		(1,284	)		(5,346	)
Interest & Investment Income		111			89			12			5			217			99			111			75			138			423			101			282			426			385			1,194
Other Income		343			252			378			261			1,234			457			1,750			435			504			3,146			469			429			517			591			2,006

Income from Continuing Operations before Income Taxes		9,887			14,921			13,911			17,435			56,154			13,411			17,314			19,501			19,868			70,094			17,904			20,962			17,496			23,979			80,341
Provision for Income Taxes		3,962			6,149			(525	)		7,184			16,770			5,271			6,529			7,080			6,957			25,837			6,949			8,187			6,376			8,348			29,860

Income from Continuing Operations		5,925			8,772			14,436			10,251			39,384			8,140			10,785			12,421			12,911			44,257			10,955			12,775			11,120			15,631			50,481
Total loss from discontinued operations		(1,708	)		—			1,295			—			(412	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	4,217		$	8,772		$	15,731		$	10,251		$	38,972		$	8,140		$	10,785		$	12,421		$	12,911		$	44,257		$	10,955		$	12,775		$	11,120		$	15,631		$	50,481


Earnings (loss) per share - Basic:
Income from Continuing Operations	$	0.09		$	0.14		$	0.22		$	0.16		$	0.61		$	0.13		$	0.16		$	0.19		$	0.19		$	0.67		$	0.16		$	0.19		$	0.17		$	0.23		$	0.75
Total loss from discontinued operations		(0.03	)		—			0.02			—			(0.01	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	0.06		$	0.14		$	0.24		$	0.16		$	0.60		$	0.13		$	0.16		$	0.19		$	0.19		$	0.67		$	0.16		$	0.19		$	0.17		$	0.23		$	0.75


Earnings (loss) per share - Diluted:
Income from Continuing Operations	$	0.09		$	0.13		$	0.22		$	0.16		$	0.60		$	0.12		$	0.16		$	0.19		$	0.19		$	0.66		$	0.16		$	0.18		$	0.16		$	0.23		$	0.73
Total loss from discontinued operations		(0.03	)		—			0.02			—			(0.01	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	0.06		$	0.13		$	0.24		$	0.16		$	0.59		$	0.12		$	0.16		$	0.19		$	0.19		$	0.66		$	0.16		$	0.18		$	0.16		$	0.23		$	0.73


WASO - Basic		64,890			64,358			64,305			64,656			64,547			64,877			65,392			65,779			66,546			65,643			67,310			67,453			67,054			67,059			67,219
WASO - Diluted		66,056			65,267			65,366			65,786			65,607			65,860			66,487			66,931			68,062			66,887			68,947			69,478			69,458			69,419			69,325

Net Sales by Segment:
Physician Business	$	216,705		$	237,370		$	243,439		$	261,502		$	959,016		$	250,544		$	255,422		$	290,010		$	290,844		$	1,086,820		$	284,438		$	300,813		$	329,160		$	313,109		$	1,227,520
Elder Care Business		113,656			126,897			134,403			139,797			514,753			136,585			130,397			133,771			131,844			532,597			128,697			126,246			129,261			129,915			514,119

	$	330,361		$	364,267		$	377,842		$	401,299		$	1,473,769		$	387,129		$	385,819		$	423,781		$	422,688		$	1,619,417		$	413,135		$	427,059		$	458,421		$	443,024		$	1,741,639


Billing Days:		62			65			61			65			253			64			63			62			64			253			64			63			62			64			253

Net Sales Per Billing Day:
Physician Business	$	3,495		$	3,652		$	3,991		$	4,023		$	3,791		$	3,915		$	4,054		$	4,678		$	4,544		$	4,296		$	4,444		$	4,775		$	5,309		$	4,892		$	4,852
Elder Care Business		1,833			1,952			2,203			2,151			2,035			2,134			2,070			2,158			2,060			2,105			2,011			2,004			2,085			2,030			2,032

	$	5,328		$	5,604		$	6,194		$	6,174		$	5,826		$	6,049		$	6,124		$	6,836		$	6,604		$	6,401		$	6,455		$	6,779		$	7,394		$	6,922		$	6,884

(1)

Quarterly net sales for fiscal year 2007 were adjusted in the fourth quarter of 2007 from previously reported amounts. During the fourth quarter of fiscal year 2007, the Company properly reclassified certain transactions from cost of sales to net sales. Such adjustments were deemed immaterial on quarterly net sales.

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

As of December 28, 2007

Select^TM Net Sales

(in thousands)


	Fiscal 2003		Fiscal 2004		Fiscal 2005		Fiscal 2006		Fiscal 2007
Consolidated Select Sales	$	101,883	$	121,211	$	137,540	$	157,296	$	185,844

PSS WORLD MEDICAL, INC.

SEGMENT INFORMATION

December 28, 2007

(in thousands)


	Three Months Ended				Nine Months Ended
	12/28/2007		12/29/2006		12/28/2007		12/29/2006
NET SALES:
Physician Business	326,520		329,159		952,936		914,411
Elder Care Business	138,688		129,261		409,112		384,203

Total Net Sales	465,208		458,421		1,362,048		1,298,615


BILLING DAYS:	62		62		189		189

NET SALES PER BILLING DAY:
Physician Business	5,266		5,309		5,042		4,838
Elder Care Business	2,237		2,085		2,165		2,033

Total Net Sales Per Billing Day	7,503		7,394		7,207		6,871


INCOME FROM OPERATIONS:
Physician Business	23,804		18,318		63,230		58,065
Elder Care Business	6,491		5,073		18,040		14,860
Corporate Shared Services	(6,180	)	(5,517	)	(18,162	)	(14,725	)

Total Income from operations	24,115		17,873		63,109		58,200


DEPRECIATION:
Physician Business	2,022		1,965		6,288		5,843
Elder Care Business	1,118		993		3,404		3,042
Corporate Shared Services	1,533		1,256		4,338		3,569

Total Depreciation	4,672		4,214		14,029		12,454


AMORTIZATION OF INTANGIBLE AND OTHER ASSETS:
Physician Business	763		770		2,312		2,293
Elder Care Business	583		669		1,867		2,065
Corporate Shared Services	16		29		46		88

Total amortization of intangible and other assets	1,362		1,469		4,226		4,445


PROVISION FOR DOUBTFUL ACCOUNTS:
Physician Business	477		492		1,862		861
Elder Care Business	1,184		1,889		1,598		2,535
Corporate Shared Services	—		—		—		—

Total provision for doubtful accounts	1,661		2,381		3,461		3,396


INTEREST EXPENSE:
Physician Business	1,230		1,077		3,539		3,122
Elder Care Business	1,960		1,960		5,877		5,878
Corporate Shared Services	(1,380	)	(1,716	)	(4,714	)	(4,939	)

Total interest expense	1,811		1,321		4,702		4,060


INTEREST AND INVESTMENT INCOME:
Physician Business	—		—		—		—
Elder Care Business	5		—		11		13
Corporate Shared Services	21		426		657		794

Total interest and investment income	26		426		668		806


PROVISION (BENEFIT) FOR INCOME TAXES:
Physician Business	9,354		6,282		24,010		21,209
Elder Care Business	1,870		1,114		4,827		3,435
Corporate Shared Services	(2,223	)	(1,020	)	(5,172	)	(3,133	)

Total provision for income taxes	9,001		6,376		23,665		21,512

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Current Fiscal Year Balance Sheet

(in thousands)

Consolidated


	As of
	6/29/07	9/28/07	12/28/07
ASSETS
Cash	23,954	17,041	15,031
Accounts Receivable, net	222,699	232,282	224,282
Inventory, net	187,499	188,087	214,256
Deferred Tax Assets	8,987	9,319	9,175
Other Current Assets	34,257	27,894	31,611

Total Current Assets	477,396	474,623	494,355


Property and Equipment, net	89,347	89,339	89,897
Intangibles, net	30,280	28,991	27,669
Goodwill	110,993	110,727	110,868
Investment in available for sale securities	—	46,147	50,206
Other Long-Term Assets	98,380	69,856	68,580

Total Long-Term Assets	329,000	345,060	347,220

Total Assets	806,396	819,683	841,575


LIABILITIES & EQUITY
Accounts Payable	144,572	149,827	161,728
Accrued Expenses	33,099	33,275	34,350
Current Maturities of Long-Term Debt	2,132	32,129	33,660
Other Current Liabilities	15,267	15,000	15,846

Total Current Liabilities	195,070	230,230	245,584


Long-Term Debt	150,527	150,449	150,839
Other Long-Term Liabilities	70,414	66,788	67,132

Total Long-Term Liabilities	220,941	217,237	217,972

Total Liabilities	416,011	447,467	463,556

Total Equity	390,385	372,216	378,019

Total Liabilities & Equity	806,396	819,683	841,575

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Balance Sheet Trend

(in thousands)

Consolidated


	Fiscal 2005				Fiscal 2006				Fiscal 2007
	Jun-04	Sep-04	Dec-04	Mar-05	Jun-05	Sep-05	Dec-05	Mar-06	Jun-06	Sep-06	Dec-06	Mar-07
ASSETS
Cash	63,112	45,591	13,657	17,888	23,836	17,466	26,651	23,867	27,784	45,678	54,904	46,658
Accounts Receivable, net	182,639	197,423	209,342	217,350	208,642	213,585	207,659	208,964	206,405	225,536	219,822	222,776
Inventory, net	112,653	113,384	147,470	134,110	132,684	136,450	167,407	173,458	170,612	172,127	186,193	174,130
Deferred Tax Assets	38,594	33,301	32,206	29,014	29,113	20,183	14,298	12,959	11,181	9,042	7,379	8,776
Other Current Assets	13,596	10,016	18,567	19,451	22,182	25,822	27,937	33,827	32,876	39,288	37,329	34,434

Total Current Assets	410,594	399,715	421,242	417,813	416,457	413,506	443,952	453,075	448,858	491,671	505,627	486,774


Property and Equipment, net	70,792	73,362	76,453	81,105	84,173	86,840	86,475	87,663	88,214	87,291	85,885	88,627
Intangibles, net	10,737	12,824	22,419	21,858	21,217	34,427	35,395	34,345	33,350	32,343	31,186	29,758
Goodwill	71,631	71,646	79,542	85,617	86,273	103,420	105,452	105,521	106,519	106,819	106,971	107,366
Other Long-Term Assets	39,555	40,794	41,691	39,965	47,315	50,862	53,665	56,371	54,983	54,935	58,063	62,450

Investment In Subsidiary	—	—	—	—	—	—	—	—	—	—	—	—

Total Long-Term Assets	192,715	198,626	220,105	228,545	238,978	275,549	280,987	283,900	283,066	281,388	282,105	288,201

Total Assets	603,309	598,341	641,347	646,358	655,435	689,055	724,939	736,975	731,924	773,059	787,732	774,975


	Fiscal 2005				Fiscal 2006				Fiscal 2007
	Jun-04	Sep-04	Dec-04	Mar-05	Jun-05	Sep-05	Dec-05	Mar-06	Jun-06	Sep-06	Dec-06	Mar-07
LIABILITIES & EQUITY
Accounts Payable	105,057	105,608	127,465	109,649	115,455	118,953	141,622	139,227	122,449	145,767	162,338	131,330
Accrued Expenses	29,667	33,610	36,085	44,880	26,660	33,196	30,413	34,499	27,748	34,827	31,670	37,224
Current Maturities of Long-Term Debt	35,052	25,000	25,000	25,000	25,679	27,786	25,788	509	517	1,655	152,154	2,238
Liabilities of Discontinued Operations	4,809	405	—	—	—	—	—	—	—	—	—	—
Other Current Liabilities	12,982	13,360	9,296	9,701	12,661	11,883	11,837	13,639	12,490	13,917	10,730	11,440

Total Current Liabilities	187,567	177,983	197,846	189,230	180,455	191,818	209,660	187,874	163,204	196,166	356,892	182,232


Long-Term Debt	150,000	150,000	150,000	150,000	151,192	151,113	150,981	150,855	150,725	150,616	460	150,675
Other Long-Term Liabilities	23,629	25,225	29,359	30,310	35,870	41,179	43,509	49,433	54,274	57,781	62,302	61,207

Total Long-Term Liabilities	173,629	175,225	179,359	180,310	187,062	192,292	194,490	200,288	204,999	208,397	62,762	211,882

Total Liabilities	361,196	353,208	377,205	369,540	367,517	384,110	404,150	388,162	368,203	404,563	419,654	394,114

Total Equity	242,113	245,133	264,142	276,818	287,918	304,945	320,789	348,813	363,721	368,496	368,078	380,861

Total Liabilities & Equity	603,309	598,341	641,347	646,358	655,435	689,055	724,939	736,975	731,924	773,059	787,732	774,975

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Unaudited Operating Highlights

Current Fiscal Year

(in millions)


	Three Months Ended						Nine Months Ended
	December 28, 2007			December 29, 2006			December 28, 2007			December 29, 2006
Net Sales:
Physician Business	$	326.5		$	329.2		$	952.9		$	914.4
Elder Care Business		138.7			129.3			409.1			384.2

Total Net Sales	$	465.2		$	458.4		$	1,362.0		$	1,298.6


Income from Operations:
Physician Business	$	23.8		$	18.3		$	63.2		$	58.1
Elder Care Business		6.5			5.1			18.0			14.9
Corporate Shared Services		(6.2	)		(5.5	)		(18.2	)		(14.7	)

Total income from operations	$	24.1		$	17.9		$	63.1		$	58.2


EBITDA (a)	$	31.0		$	24.1		$	83.3		$	76.5
Income from operations, as a percentage of net sales		5.2	%		3.9	%		4.6	%		4.5	%
Consolidated Return on Committed Capital (“ROCC”) (b)		26.1	%		23.9	%		24.3	%		25.8	%
Billing Days		62			62			189			189

Net Sales Per Billing Day (in thousands):
Physician Business	$	5,266		$	5,309		$	5,042		$	4,838
Elder Care Business		2,237			2,085			2,165			2,033

Total Net Sales Per Billing Day	$	7,503		$	7,394		$	7,207		$	6,871


Net Sales Per Billing Day Growth Rate:
Physician Business		-0.8	%					4.2	%
Elder Care Business		7.3	%					6.5	%
Total Net Sales Per Billing Day Growth Rate		1.5	%					4.9	%

							Annualized
							December 28, 2007			December 29, 2006
DSO (c)
Physician Business								42.4			41.0
Elder Care Business								50.2			53.2
DOH (d)
Physician Business								52.8			49.1
Elder Care Business								55.3			55.2
DIP (e)
Physician Business								46.2			45.3
Elder Care Business								28.0			29.8
Cash Conversion Days (f)
Physician Business								49.0			44.8
Elder Care Business								77.5			78.6

							As of
							December 28, 2007			December 29, 2006
Operational working capital (g)							$	276.8		$	243.7

Net Debt:
Bank debt							$	32.6		$	1.5
Other debt								1.9			1.1
Convertible senior notes								150.0			150.0
Less: Cash and cash equivalents								(15.0	)		(54.9	)

Net Debt							$	169.5		$	97.7

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

EBITDA Calculation

Current Fiscal Year

(in thousands)


	Fiscal 2008
	Q1			Q2			Q3
Net Income	$	8,687		$	14,483		$	14,162
Plus: Interest expense		1,358			1,533			1,811
Less: Interest and investment income		(528	)		(114	)		(26	)
Plus: Provision for income taxes		5,559			9,106			9,001
Plus: Depreciation		4,599			4,758			4,672
Plus: Amortization of intangible assets		1,458			1,406			1,362

EBITDA	$	21,133		$	31,172		$	30,983

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

EBITDA Calculation

(in thousands)


	Fiscal 2005															Fiscal 2006															Fiscal 2007
	Q1			Q2			Q3			Q4			Total FY 2005			Q1			Q2			Q3			Q4			Total FY 2006			Q1			Q2			Q3			Q4			Total FY 2007
Income from Continuing Operations	$	5,925		$	8,772		$	14,436		$	10,251		$	39,384		$	8,140		$	10,785		$	12,421		$	12,911		$	44,257		$	10,955		$	12,775		$	11,120		$	15,631		$	50,481
Plus: Interest expense		1,942			1,817			1,737			1,360			6,856			1,509			1,358			1,561			1,456			5,884			1,406			1,336			1,320			1,284			5,346
Less: Interest and investment income		(111	)		(89	)		(12	)		(5	)		(217	)		(99	)		(111	)		(75	)		(138	)		(423	)		(101	)		(282	)		(426	)		(385	)		(1,194	)
Plus: Provision for income taxes		3,962			6,149			(525	)		7,184			16,770			5,271			6,529			7,080			6,957			25,837			6,949			8,187			6,376			8,348			29,860
Plus: Depreciation		3,482			3,427			3,727			3,605			14,241			3,316			3,468			3,673			3,475			13,932			4,094			4,145			4,215			4,296			16,750
Plus: Amortization of intangible assets		836			935			1,278			1,488			4,537			1,361			1,389			1,677			1,871			6,298			1,505			1,472			1,468			1,463			5,908

EBITDA	$	16,036		$	21,011		$	20,641		$	23,883		$	81,571		$	19,498		$	23,418		$	26,337		$	26,532		$	95,785		$	24,808		$	27,633		$	24,073		$	30,637		$	107,151

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Return on Committed Capital (ROCC)

Current Fiscal Year

(in thousands)

Consolidated


	Fiscal 2008
	Q1		Q2		Q3
Quarterly Average Committed Capital (1)	363,905		387,926		403,493
Return on Committed Capital - Quarterly (2)	18.2	%	27.2	%	26.1	%

Return:
Net Income	8,687		14,483		14,162
Add:
Provision for Income Taxes	5,559		9,106		9,001
Interest Expense	1,358		1,533		1,811
Amortization	1,458		1,406		1,362
Interest and Investment Income	(528	)	(114	)	(26	)

	16,534		26,414		26,310


Committed Capital:
Total Assets	806,396		819,683		841,575
Less assets excluded:
Cash	(23,954	)	(17,041	)	(15,031	)
Goodwill and Intangibles, net	(141,273	)	(139,718	)	(138,537	)

Total Liabilities	(416,011	)	(447,467	)	(463,556	)
Plus liabilities excluded:
Current debt	2,132		32,129		33,660
Long-term debt	150,527		150,449		150,839

	377,817		398,035		408,951

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Return on Committed Capital (ROCC)

(in thousands)

Consolidated


	Fiscal 2005										Fiscal 2006										Fiscal 2007
	Q1		Q2		Q3		Q4		Total FY 2005		Q1		Q2		Q3		Q4		Total FY 2006		Q1		Q2		Q3		Q4		Total FY 2007
Quarterly Average Committed Capital (1)	247,761		260,802		280,166		303,738				316,837		322,662		325,748		330,989				340,070		341,619		331,779		338,812
Annual Average Committed Capital (2)									274,084										321,764										341,411

Return on Committed Capital - Quarterly (3)	20.3	%	27.0	%	24.1	%	26.7	%			20.4	%	24.7	%	27.8	%	27.9	%			24.4	%	27.5	%	23.9	%	31.1	%
Return on Committed Capital - Annual									24.6	%									25.4	%									26.5	%

Return:
Income from Continuing Operations before Extraordinary Loss	5,925		8,772		14,436		10,251		39,384		8,140		10,785		12,421		12,911		44,257		10,955		12,775		11,120		15,631		50,481
Add:
Provision for Income Taxes	3,962		6,149		(525	)	7,184		16,770		5,271		6,529		7,080		6,957		25,837		6,949		8,187		6,376		8,348		29,860
Interest Expense	1,942		1,817		1,737		1,360		6,856		1,509		1,358		1,550		1,467		5,884		1,406		1,336		1,320		1,284		5,346
Amortization	836		934		1,278		1,488		4,536		1,361		1,389		1,677		1,871		6,298		1,500		1,477		1,469		1,462		5,908
Interest and Investment Income	(111	)	(89	)	(12	)	(5	)	(217	)	(99	)	(111	)	(64	)	(149	)	(423	)	(101	)	(282	)	(426	)	(385	)	(1,194	)

	12,554		17,583		16,914		20,278		67,329		16,182		19,950		22,664		23,057		81,853		20,709		23,493		19,859		26,340		90,401


Committed Capital:
Total Assets	603,309		598,341		641,347		646,358		646,358		655,435		689,055		724,939		736,975		736,975		731,924		773,059		787,732		774,975		774,975
Less assets excluded:
Cash	(63,112	)	(45,591	)	(13,657	)	(17,888	)	(17,888	)	(23,836	)	(17,466	)	(26,651	)	(23,867	)	(23,867	)	(27,784	)	(45,678	)	(54,904	)	(46,658	)	(46,658	)
Goodwill and Intangibles, net	(82,368	)	(84,470	)	(101,961	)	(107,475	)	(107,475	)	(107,490	)	(137,847	)	(140,847	)	(139,866	)	(139,866	)	(139,869	)	(139,162	)	(138,157	)	(137,124	)	(137,124	)
DTA from sale of Imaging Business	(28,444	)	(26,923	)	(26,746	)	(15,758	)	(15,758	)	(10,487	)	(6,184	)	(912	)	(3,614	)	(3,614	)	—								—

Total Liabilities	(361,196	)	(353,208	)	(377,205	)	(369,540	)	(369,540	)	(367,517	)	(384,110	)	(404,150	)	(388,162	)	(388,162	)	(368,203	)	(404,563	)	(419,654	)	(394,114	)	(394,114	)
Plus liabilities excluded:
Current debt	35,052		25,000		25,000		25,000		25,000		25,679		27,786		25,788		509		509		517		1,655		152,154		2,238		2,238
Long-term debt	150,000		150,000		150,000		150,000		150,000		151,192		151,113		150,981		150,855		150,855		150,725		150,616		460		150,675		150,675
Liabilities of Discontinued Operations	4,809		405		—		—		—		—		—		—		—		—		—		—		—		—		—

	258,050		263,554		296,778		310,697		310,697		322,976		322,347		329,148		332,830		332,830		347,310		335,927		327,631		349,992		349,992

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Annual Average Committed Capital equals the sum of the committed capital of the most recent two year ends, divided by two.

(3)	Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.

PSS WORLD MEDICAL, INC.

Footnotes

(a) EBITDA represents net income plus provision for income taxes, interest expense, depreciation, and amortization of intangible assets, less interest and investment income. Management reviews EBITDA when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes EBITDA is an important measure of liquidity.

(b) ROCC equals return divided by average committed capital. Return is annualized for quarterly and year to date calculations. Management reviews ROCC when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes ROCC is an important measure of profitability and return.

(c) DSO is average accounts receivable divided by average daily net sales. Average accounts receivable is the sum of accounts receivable, net of the allowance for doubtful accounts, at the beginning and end of the most recent four quarters divided by five. Average daily net sales are net sales for the most recent four quarters divided by 360. Southern Anesthesia & Surgical, Inc. (“SAS”) accounts receivable balance of $1.4 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(d) DOH is average inventory divided by average daily cost of goods sold (“COGS”). Average inventory is the sum of inventory at the beginning and end of the most recent four quarters divided by five. Average daily COGS is quarterly COGS for the most recent four quarters divided by 360. SAS inventory balance of $3.9 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(e) DIP is average accounts payable divided by average daily COGS. Average accounts payable is the sum of accounts payable at the beginning and end of the most recent four quarters divided by five. SAS accounts payable balance of $3.8 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(f) Cash Conversion Days is the sum of DSO and DOH less DIP.

(g) Operational working capital equals accounts receivable plus inventory minus accounts payable.

GRAPHIC 4 g45280img01.jpg GRAPHIC begin 644 g45280img01.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`CP$-`P$1``(1`0,1`?_$`-```0`!!`(#`0`````` M```````(`0<)"@(&`P4+!`$!```'`0$```````````````$"!`4&!P@#"1`` M``8!`P("`PP'!0,)"0```0(#!`4&!P`1"!()(3%!$Q11(M57EQAXV!DY69EQ MD;,5%K<*88$R(Q>A0E+PL<%#)"76-QKA8C-3DT4I27D1``$#`@0#!`8'!0<# M`@<```$``@,1!"$2!08Q00=187$3@9&A(A0(\+'!T3)"(^%28I(ST.). M,#:F6'BAS!MT]6$D` M](!YCJ#JT]VE>]0)(%0"X]@XKT4G:*[".XMA,3T3%OIUP+6%82$@T:O9AR3H M]8WB6BRI',BLD"A1.5$IQ(40$VP>.IFLFD:71QN+&XN-#0#M*\O,B#@TO`<[ M@TTKZ%[\!`?(=_$0_O#P$/[AU!>RKHB_`Y?MFPE*LZ;(G.7J*19=-(Y@]TI# MB`B'Z-3M:'+PDE,7')_><&_6O*FN18H&1/U@(;@8H@8HA[H"&X>G7F7@'A7P M46D/_`[U.:[ZBO(8X%Z>H1`1\`]'CMOX[^`:#S78M:*+W`=3`%Q52*E.`"3< M0'?8=AV';S\?+4U",'8%1RD"KL.[FO(&^WCY_P!GCJ![E+ARX*NB)HB:(FB) MHB:(FB)HB:(FB)HB:(FB)HB:(H77;[Q'C-]"[G+_`#Q[>.B*U79Y^Z^X/?1_ MIG[%?1%DFT1-$31$T1-$31%Q,.P;^6E">"B!4JW>3\KXYPI1+'D[+=YK&.L? MU)DI)6*W6^6:0D%%-$P\!7>NSD*9=>7-4UW>VMC`ZZO7-BMF"I05<._4@55RC'EV M4'<,VQ]`Z?6;-0W\\7>J2-JRQB>6FI_S'M]X!M0>7#*J;KNG6FV& MN@T]AH^Y>T&O]D$4QX85/.H6:+CEPUQIQ^22M+N5O&:# M[L430UK1R!H*O-,"YU2:`IXE7BL^6R MU5V9JOCC+:A!CGBSHR>WELGU#Z`$?#5H)#03V*DNM= M=:.RNL[^7OBAS#_NKZE;B1YCX&KX`:Z6J9QN`J`B?_4O'^0**@BIZ2+2=AJ[ M2'+T[>(^T=(!X[ZIFW49XX>(/[51/WSMVU9FU.62S?\`NSQ2,/VA=GA+QQIS M\CU5ZX86S`B)#(A^YK#3;HJF5/8QT`*S>/G"'1ON8NQ=A\]>XDB(P>"3X+VC MU7:^OTRW&GW-?RA['.]1-?8NK6'AKQCL_69YC!G&K*&$QW%1L5QH[TIRB(;E M<4RP0+D@[^X8-2-@B))CI7Q/WX+PN]C;2E&62RCBE/#RZL./>P@*Q]C[=U>] MG<*8AY.\QL&R)B*'9#5^0=RN$`W7V$43N:SDUQ<6CMJ0VPBB55(#@&PCZ=>+ MK'WL7R5_ME8O>]*X#;/=HNKZYI]X:T=\7+*UO<(Y'%M!R`H`,`HKVC!W>APH M55_A?E_B'E'$M3]:=6S?C.&I-I>)EV$6P34*0K)PL8!Z0$TDS`P^(CJE?;ZS M"28IFR0C\+2UM:=[AB?$XK!+S;7S`Z$T7.V=RGYORT[N:QS_P#I'7=J7+=.ZG[>NK&4.RNFAJZ( MU_,T.!J`*5H[BLO7&WG)Q@Y91+=[A',%6LDPLV!RYI+YRG`Y"B`$-SDE:5*F M;SB`H_[QR)*H^("!QWU>+>[M+IHDA(+:]N*WSM#J/LS?,`DVWJ,,[R"2PD-F M;W%AI7T`U[5+9(PF*`B.X^0B'N@`;^YY#KU<*'#@L[;4"A-?10^D=J\FH**: M(FB)HB:(FB)HB:(FB)HB:(FB)HBA==OO$>,WT+NWCHBM5V>?NON#WT? MZ9^Q7T19)M$31$T1-$31%Q,.VW]N_P#L#?W=0KB!0XJ%?>`[5:+.6<,:\=,3 MWG-F8+5&T_&^/(-Y8+//OU2%*W:-DQ!%DS0.H0\C,RKTR;5FT2W6=.E2)$`3 MPTS3;W6K^/3-)C=-J$CPUK!B23]0`JXDX4"IKJ[ATVVDO=0>UD$8+O$#E MX]BT?F]CY3_U+O-1:K'=6/#O`/!4XQL':GAW!]#;TW&V/8 MLD?7JG76_KG!MU#*/'SM9TH#N9G)9TJ=R\>.53N72YS*',)AURS>:E>ZU='5 M=3>]][*XDEQ)//U8=E%O>WL[;1;1MK:15MF-]UC0*]_94\R3V+\LIR"@(-RJ MWL-"S+",D=A7FU\3VV6A"%W\S.ZPTG%2DV#Q-ZO8H>>VJ4_IM,A-0,>WZ>E4 M%UN*RLAFO8+MD7,B![QZF!Y/@`3W+C3.4''K(,H->I^9L=2-D`_JSU5:S1\1 M;B'`_JS%/4YM6.L9-C>]W,U``-X>?AKR-S&XY!B^GTXT7C9[KVW>S&"TOK0S M?Y9D9'(.XQN_4![BT*^ZA4U4SI*]"J9R=*B2A2G(HD8!*8JA#%,4Y#`.P^&P MAJ>-CJ4>`LA/OMP(RGMX>NA!4*.'W(J9Y7XA@^AX/'S/S-&X9(8PC M,I16CJU:2%:2EJ,@W3Z4TV[R.=].P$17/X&MDEEJ%FW-8/SM&.5XKQ[*46H= M8VIUBZ<,=J6P-3?K>WXA5UI=_J2AM<0QWNN)I@*&N%:%76X8=Z+`G)2S-\29 M6@Y#C9G,JZD2:JWQZ1*JSM@:*$:N82"LTDG$KL)\[H1`D9*-6CHVW2F98X"& MJFTU2*X=Y,ONSC`\A7G3NKPQ5[Z>_,+M3==V-`W#&[1MU-.5\5P[+'FP%&O= M3$G@TBO*I69DHE,`>(=0AU;`/B.WGN`>8?[-5^09LP)H5T)[K@"T8G'A2JZ/ MD;%N/&/:6.`+>_%6W5]$TC<%F^PUNVCN;*3BR0!P'(Y:4H3V\>]:M_/CL9V? M%+MYG_@-)611*JE&QNL/EEY-:^P#E@J=Z,KB&TIG_>LB9D0H&3B5U!>;E'U" MZIA*B&.WFDO;.;RS]UH`]T=W&G[5Q1U.^6C4-NRG=G2=\K'0GS'6[9")FD8D MQ.%*C^$@D#MX+T/;\[[MYHLI%X?YQ.7]IK:\BVA(W-BD<5M<*4L#DL>JGE"* M21:#.1+18-G,@FF219B4YG";@-Q)-:ZQG?Y$_P#4KQIP\>W'FJ+I1\T&J6%\ M-M]2&OE@\WRQ.8`''T#9+N?*&H8YGL>.[BYBT,.Y><1,70 M,XQ4FVD:"E99YL"]=KUQE"+`TKS>X"(%A)7UBD>_<&!L#&NX-<32N!IBI/D/UB.PE,7 M8H@)=O(?[QW`?,!].^IP6N%6K*&.+JD8L/`_9W]M>!JO)HITT1-$31$T1-$3 M1$T1-$31$T10NNWWB/&;Z%W.7^>/;QT16J[//W7W![Z/],_8KZ(LDVB)HB:( MFB)HBXG\@\O,-O\`V>Z.I7OR-S<_MY*!:74IVK0/[_7.C('.3F!5NW'QN65L M=#QWDN$H[N"BA`$,IK1,3K; MH[M.RVAMEV^M:&6\DC<\9L`V+CAP(+CQYTH%SAU(UZZW%KS=M:8XF!DH:=P<#3"@Q`Y>M;@W;LX-X\[?W%S'V`*.D@YF6#(EBRE;BD*9Y?LIS31J-LM# MI84TU!9@Z1!I&HB`%:QK=!(`$2B8W.N\]UZAO'<,VN7SC1YRL;R;$W\#!V4' M$\2>*WIM[1K7;^DQZ5:-#'!@+B`*EQ&)]:G3T>&PB(^Z/@`CY^Y^G6+`E7H- M.4-))(Y\U7I#80`1#<-MP\P_0.E:\5$BHI4^M1_SSQ7X^\FJY_#6<2J**1RIMGQSN46*@%!XW,F(K MZM5Q\98`R0/,D`XAW$4["%SONX]1^AN77-`N)-7Z9QT;);3T?+"TN-,CFC.0 MVN#C_>!JLQW$SEQB/F9B.-R_AZ45<1*[A2+GJ_+)D:6:FV-H0AI"N62/(HL5 MN]0ZP,DJF=1LZ1$JJ)S$-JXVES'>VXG@/'EV>*W_`+(WSH?4#0F;@V]('6CJ M9FNP>P_F#@.%.7:I."EU%+N<=P'??8``=_/WOEY:J@X@K+P'9:9C7M&%5@L[ MO':QK/*"C6+/&&*VVC^3%3C@D9!O'F38M\PUN)2%5U`2S:YEZ]=$+3>]E)NK;S?+WI:,,E6@-$ M[68T=0?C:/PD8NI0U*B)V5^Z1;;38H?AKR4L+J9F5&IXS!5]G16--N%H9JJ+ MC%EQ?.#$<.Y%LS;&_=#A8OM)A1.T6,93U.O#1]1=(T6ER*2,%`>;J=M>:U]\ MN'7._P!6NSTZWI,7:GE#;:68D/+VX>4\^CW3QY=BVD$A$R91-X"(>/H\=Q]W MQU>JUQ7;HX"M*TQIPJ.-/2JG(!P$-Q`1](>8>X(?VAJ(/;P4S:-=FY_6M7/O MG=M>!&!G.;.$*ZG'SD6L9AF878 M2AO#-4D./90\BL7/#_N#PM&XB* MJ*:Q50/'5B2GETI-JJ(>JC'C4X@)2+`!;7;W[WVLUI<'W"/=//AP]/L6C^G/ M66TL=BZWL+>$TEQH\M@]UH,2YDH_"QIXMQ]ZHQ#AAQ*VI>T9DK)N5>W_`('M MN5%WDE:$XB9K#.=D@/[;9:U4;%*UVKSKI8YC*/5',/'IIBX'WSGU/K1W$^^L MBTMTDEA&9?QTX]O8N\.@^KZKK72_2[[7G/\`BS%E:78.,321$37GE%*G$TJI MBU?.E1L&2;%AN0,I5\JUN*;616F3ADT7<_3GSA9HPNE->%-[)::VHZ;F0.<@"+M)`QD^NO(:T5'$ M<^"O.F<3%`1VW].VX!OX>@?$//4M:G#\*OP,WT+NN=1 M)`D;&0WE5QP%/#CZ%J!?TOW%G_6OFEDOE#=`7GV/'&H*NHB2DMWAWF8\OKRS M!M-.U')5#+R+"L,IAR)Q-UD=.$U?$=AUTO\`,#J\>D[9LMOZ>[*R[Y##+'%@ M13F'.+3RX$8K1_1_3SJFN3:U=QU\@9JG&KWGW:'N`/D&WEZ/0'F M/EKCJAJ*'W`."Z1#3F+R:N)^@14QR)G,0H'.!1$A#&Z`,;T%$X%.)0$?3L/Z M-3!'%P;[M"[E4T'KH?J5E9_/5-HLHRBJ)!U&`;\ MR!S6X8QBB'0255CE5##TD(8P"&HN&5I<2*`*QW.XK#3IA#JPDMFN-`]X_2\3 M)7*T=[LJNQ&3<9.1Z,I"/V,Q'.B@=M(13UM(L7!!_P"L0>,U5FRQ`]TIAUYA M['&@Q';R]85X9/#/$)K9S9(7"HR>+J*M$*9D) M\Y:4-\HJOTE4E<;WTJT6=Q[Y08[K`V_7X8Y`V33M5%O%_P"W`2>-%N`=8AX=/EX>8:R(O8#0U]2[[ MH[E2GI^Y<3!U;;#X;^/@/]VP^.P@/]FI0^.M75)40TT(/$_0K1.[R^!W/%'G ML[R!C(RE6CLH?N+/M+<1@^RA`WQG.+?Q0:/]25`K9-M<(LDB4A!V(#T2CL40 M#6(:I&ZTU`70)$3C4?3EC[%\NOF.VXSI[U:9N#2&NA9=@749:*`2YO?#:84J M/14+&U-NP.N-;U"UM6-XB21@=_*'%Q[J`K#MG[O;X"O,98L/<3 ML-9(YC7RWQ+I<['X^>(3#56.Y_F%VSJUO<;?V-IU[KVIW$9B(9"6P4=4 M',]P)-*UID`-1[_%:=62L=W/$&0;1CC(=34JMTIDQ[!8Z5).$G?[G="BVDD( M-VY9.7"3I$(]TB03IKG$R9O$_7N.L5N&/SN93(6/\:]R^<>N:7>[6-4LU\6,L4^UT M.W,^@CQ.,MDJUJEEK+O)9[UD8LN_1'3I`-'6)@CU&,?V9E/,7*:0B(B*12B/B.JVW>) M+9DG[P!]BV_L?#Q5KQ_,#V8*1NO594FB)HB:(FB) MHB:(FB)HBA==OO$>,WT+NWCHBM5V>?NON#WT?Z9^Q7T19)M$31$T1-$ M7$P[;#^G_8&^I'AV#FG`'ZR`A-`3V"OJ6E=_5FVHH:\J$[+,5$% MM:,:T'M<2XD>-5E/2&T;!M1MQ@9)Y'$GPH!]96S+K2:VHN)]^D=AV\AW]S80 M'46\5(_\!QIWK\;END];+-'"*#ANY3.DL@Z1*LW70.`E.DNBH4R:I#@.PE,` M@(#J8M:00[@11>>1MS"6RT,3L*$!U1WM=@HDW+@OQ_M$M_$M>A[5AFV`8RG\ M38`OMNPR\67.L#@[B3B:/*1=4L"HK!N(R,<[ZO3OJF^'BX@>]VC#ZL%AVH=/ M-M7MQ\9;-GLK[-F\VUE?"XGO:TEE*XTRT/`X+TKCCKRBKQ#EQUSEN[ENF7_L ML9FC$&**^U44FU= MY6S"W1]Q3M%,!<6\5P3XO):ZG;0+6)[R#+DG)\K.+..\K6K"][S"C&L?]/W^ M&ZA<*6^.VL^2(UC5V-T86*RVE/VMS8HM59K[" M2?5XYVH$-TI>K4ZO\8;X[K,=PYT8N"QPI^6OVKBOYGKC>D>LZ=8;XN--N)VP M/>UMHU[?*:7$`.,@!-:5''J?[.&JG1[3L7WNVJFUTMDMNU[9)&L(_"#@.2 MW+TJZ.:YNKIGIA:/HT+;71[6"U@!I2)C68=]`*\!Q6@/W8[-$VCN+F5J!F3@5\F/F%N[2_P"K M&L2VX.1LXC!J#F>V@=3QY!;E/;8;J8I[/#B%K_P#<_P">TGW&\AT3@SPK:2%_J,A= MF+B3L#5FLS1R==HM5Q^[2Q*[GI4;8RI[915^ZD5TT4W*B0+!_D(IF5L^HWS+ MQGP4`)<3QY8>VE>:Y;ZU]47]8-9M.EW3UC[G3GSCS9&B@E<*T(YAC#5Q)\>R MFT+Q,P2SXS<<\.X)9/RRA,:T6(@'DH7J$).;,4TA8I),3`!@;OYYZX52*/B5 M,Q0]&KW;M$=JR,<6@`]GH79VQ=LLV9M73]L1D$6EJUKZ^C_3/V M*^B+)-HB:(FB)HBX&';;^\?[@V#]>XZ\Y'!HJ>`J3X`)W]]/6OF9?U#643Y. M[K&?VA''KF.+87&^*8\O6TN(:?Y:+D;JY>?%;ME`KDA8UGI''VU6VW_33"V'M2 M8K]G,4QRY0SF#L`#8R;D5%3PR-^VJ MWATHQV9!VA[P?6/L6?76IULE?BD6ZCMBY;(NG+%9=(R:3QH*17+50W@1='UZ M2Z`J)&]\`'(<@[;"`AX:B!4T4DA<&')B[[^?HXJ)%GRWG7"LRX-?\33>9,6H M-@<)9+P8R_>MZBC=72=M<\(K+_OE\DW2#K,_K;J1%4/_`+]P_S:XJ9XD'$%C'-](F M[8Q*J,G19&0-5K_$*('!)RWE:/:DH6TL7#9;I5_)R#@Q46K9(#JKKG*0A1$P:])'-B: M72$`#MP5XU[<.D;:TJ76]9F;#ID+:ND)%.X#&I+C@T`8E:U_;[Q1?^XQSVN_ M7M]:Y"Z6[>U7JQU2EZT;AA?%M^!Q^#8[!SO+&6%H8 M32C1^H3F($G`FM5M*@8!#R*/AX^0C_;Z=]7DS0@T+@NTPT/Q!::]R]-8Y^&J ML#+V>Q2+.'@:]&OYJ:EWZA$(^+B8MJL^D7[Y8X@5%LS9MSG.;?P`NIL[!SPH MJ6]N;33K*:^O7Q,MH6%[GNP:T-Q./;]:T$\W6.\]V?N22#?&R#U6-R/;F=(H M:HH*E)5,*4S_`+*K<))-<2_NY)"#(ZF7!3;![4Z!+83F`!Q9[WW^H.8RI8'< M^P>NU0=Y"CZR_/C_`!I_$$:K9[?;5B"U@&+> M#0='D@C2RJR9WCCU?0W;$4.(^]V&CN+AMNTS.<,@'"N)/A],%K3J+U*V_LC; MUW?/NH7:M%"_RH6N:Z1TCA1ON@\`14]@JOGGA8G]GR+_`!9<&#V_S=GN2]LM M4.19\$A=W\I-*2\VP%5HW>RA4IQXY.FH=)(RI2JCT^^`-8?&YSK@R2`O836@ MQ7R/LKN^UG<9UF>V=J%R^Y,CH1F)SP`78$NR.NO6[RH]?(T/:,3(VMA<7,'ED4]V)H/F.`:,7E MN7#*<5L#\'NV[QZX*UUPECV*5M619IN1&UY\12IQ*ZFZ:='MG],+5O^S1>;J^6CKF0` MRFO$-/Y&D\AQYE9`2E$!\M@VVVW\O+RV`-58%,!P6U1SKQKQ[?%<]11-$31$ MT1-$31$T1-$31%"Z[?>(\9OH70`&P>6OHGT_A\K9&E6\?YM-:1_:R@E<5;ZG\ M[=EWYIQ\\U\*E;AO]*7E5M9^$>9L2F6*:2Q+R!DY,$!.854H/)=4@)B/.*9O M`J2DQ#20%$/`3%-Z0US-\P&GN@W9;:A3W9[)N/\`$UQS#T5'CR6]^C-V9MN2 MVSCC%.<.XBE?8MHS6B%M]<3#L`C^C^WTAJ(XJ!#B*-_$NHV>YTZF-!E+?:ZU M56.XE*\L4W&PJ)C%#J$J:TDY;$4/X>!2CU#Z`U%Q:&$N_"!B>Y4DU[IUFUTE MU<,A:T$N+I&M%.TU*QC\H++Q2SXQ?QL!PSDNK@4-R)&U;Y);5X_3C+Y^+<.?*I-*>O!:DW9<;/UV M!]OI^B2:[J[G4#H8C$S,[`%]Y1C6M!.+@\TXK'I3>Q]E_-U>L@\D\ZW'!]+E M)H\[C_C)C3(MGS54,;.DR"@P<2MGR9+NF4XZ:MCG*"+-L0J1CCZMT!-BZI!I MLUV,]V\M=V#%:@L/EQW'N2UG.[M5NM/T^23-%80R?$,B'(.>]V5Q'=6N./!3 MBI_#?N5X(K$;2\'\\L5V6EUF.0BZK5,M<:8)@C'QC0G2TC$I"CR[F[C=9WMTJ4FO(&\ MM!\*U[EA7R9S_P"XSW-FK_B!1*E2[&VF9YN-H-@:(L<7'6&#CW*B:1K3<+%/ M*,HC&[ISTN#JN@9%>>J(4P"'^6:UNNK^^!MK<5?S(P&'8>Q&CJU2F$L1\:(6RW1 M-LRE;I>K)4;=9F,,UZ3IU^%?(R1DXJ!5=E!PLDF@8SA4"&4ZN@H!601:O;1C MRHF>;05)(^]9ETYZ4?,#TW=-/MVSTN.]N`&F2:2&22-HY!P>1CSIFJI>2/'O M^H&R6[33LW*;#.)&"AMEE*0[BT#(%..X]*,7CEPZ.8@#L&SD!'W0'QU[&UUF M?]5\P8X_E'+[._BMA.VG\TVLSDW>M65E$3CY3AARP#&$BO'\7W*UN;.VUFVB MT*CK.?X:MU.XN!.//[#].*M&O='=RV6FG6NI>^+EFE19BXQEXKW`5:7' MNRE:^N,.,%UY=<@);&W$BI7V[0RLDF#2T9&69^W0E7%7U!;KE&-`MY?@CV^<-\'\61=1K\5%W')"JII>[Y:F8*+_B M6?GW:"1'*,2Z,BJ\@ZO'$2!%BQ35V32+U*"=4YSCE=C8LLHA'@2<2>]?3;IG MTFVYTUT&+3+*..;4#1\MPY@+WR4HGS\] M5Q[EM&GO57/4$31$T1-$31$T1-$31$T1-$31%"Z[?>(\9OH7[L(?KU]&MA$'9.E2LQ(L8P/Y0"N(-ZBNZ+XC\0G-/Y MBLS?]+CR.;XKYT7;!DQ(`UA.2F*7C.(;K.2I('R)B]PM:84I$S[$6=2%6=S2 M9`#WXF*4`WWUJKK]H+[O;,&LQ,)\5L7HMJOD:S/ MIDS@V.:(EM?S/!;0#OIF*^A(4P&`-AW_`+MO^@-<=U`(!XG@NFOL*J(;AMJ* M8\N*ZI(4:G2CM%_)U.MR;YNJ5PW>24)&2#ENX*(&*L@N\;++(*E,&_402B`Z MC4`%4C[&RED\R:")S^TM!/HJ"O=.E6S!`57!CIH)@`^\367$-@'8I$TB+*`' M]@!XZDS`\6_L52[*QG`-B:.0I2GP4S$MZE M5%3D)[TO[P=P\9"I@H(;%.HZ(F(^9@#7L`X-+OI]2Q^[W#9Q.,;([NXD`_#$ MPFO<*Y17TA1.L6>^?V0'(PN">%$-C2/<@L@GDCE3E6K1LU8!=;FZE:F3:;7V]%;6M*>;J M,P8/_MX2X_\`U%%67[2^8>3-DCK7W">8]US9%1\F24;84Q3%EQGB2.$ARJE9 MHI@NJZ500$H$!PFT0D!*4!]H`PB(T0L)YR3J,A>T\FX#T\^Y87+T.UW>-X+W MJIN&YO[9KJ_"6S?)MZ?ND"F`[5E@P=QTP7QPJA:;@[&-3QO!&]69\A78 MXB3^672*($=3TTN=Q,SSSQ'_`#G;A=3Q\]7&...V:&0,HT#D`MY;9VCMO9]D M-/VQ:16EI0`Y&XNH*5UHS2$#Q*KM7US1=OVQN]:N[>U MMF@G-+(U@H.RIJ?`5*Q+97[P,)8I!S1N!."\F%*>6*D<>HP-P1;"'FZ(&J)^H^[6UC=*.UO#VTKV%:.UWKO:W$S]-Z M::?=[AU5PP?$U[;>,T'YW-;FI7'@*@@.P4/XSM45QB`\=K,)%Q5F2R_^9#1ZC15:CT\'#`?4G=HA+RRJ8CZU<#[CJE993WLGQ-V M\M'[G93TGCS6OXNA_4/JG?1:[UAU-T5D'5;8Q8-:T?A!#3D!/YCB[M/`K/G@ M3C7A'C)2&V/\'8YK^/:VB=-PZ2B&QC24T^2(!/WG8IITHXEI^4.&^Z[I94WB M(%Z2^&KJR"&(!K``!]?;W^E=1;9VAMO9UB-.VS:0VMM3&C1F<:`5<>)-`/L5 M]2AL'_+?7J34K(F-+&Y2:KEJ"F31$T1-$31$T1-$31$T1-$31$T10NNWWB/& M;Z%W.7^>/;QT16J[//W7W![Z/],_8KZ(LDNX;[;AN/D&_C^K2AXI0\>2=1?^ M(/<\P\_"IU%_XB_K#4>/!.>7FN!SAX;" M`^GPV'P#;) M]!(4Q3#V:WJM;8U.!?251M,D,4W^\`[Z^AO2^X;/L73,A!RVC0:&M","#W]R MXKW["(-V7K.!\YWC2I(/A0J)O'W,]HXYYSQ'GRE+*I6?#N0:QD&+314]69^% M>DT'4C#JFZ3![+.Q/M#)P.!AE8'"AJ#48T/.G-7+W#P\0\?+Q\_T:I*%5="FX;;[ MAM[N_AJ!PXHJ")1]/B'GL/CY>D`\]0J%#,*D#B.7[%XA$H^?B7P]]UB([[^X M'OM]>F4^E3$AK?,.!_LKS;A[H?KU)0J'VKI,TQO3I14L#8*_#-CCLF9[5GTT M](40V$P*!9XQIUE$=R[I&+[H#J>H/$A45Q'?RX03,9XQD_:K.N\#W:Q.'I[K MR,S))QKDQC(P-04J6,6;0BA0`Z"4M2ZVRMRA!]`GDQ.7T&W\=4CHI"ZK''U@ M*S2:!?W9+;_4+AT?9%2+T5&*Z,';\XA24LA8[CA2%RE9FIP.C8VCW/:/0T*5U=JE:J$0A`U2N0E7A6O5[-$5J(80,4WZO/U$=&(-&B M7@`>1`U[`,I[H`;V+,K*RM-,A^&T^"*"`<&QM8QH\`T-',\EV!,I2%V*`@&X MCX^>XZ4`P%**J8W(VF)\35>313JFX!YB`:A4<.:<,2FX>Z'Z]1&)H.*A4>M. MHONAZ/2'I\OUZ4(XJ&9M:5%0@"`^0@/Z!U"H.`.*F5=11-$31$T1-$31$T1- M$31%"Z[?>(\9OH7 M.J*74[6WD,,A=G'("HX5[5H+>?S#;.V3N:7:6K0WKKV(MS&-F8',QKQE%:G! MPXY?'JI!(BG;D? MA^[7CVT&/^#QWP]ERR84H6,\M<@[=2G[F+M[S%D;&N8"-D8X03EF+% M\Y>X$_4%AFZOF2VKM_6YMO MV-G>ZK>6[BV4VXJUI!H17'@13QP'`JY]'[PO$ZV\>LC\BYA#)>/J[BFP1--M M56O%-4C[:ZNTXU6>1-/JB23Y>)LT\\00,H9!!T!FR7^:X!)/WPU$.IVTEN^< MU8UIH12AJ1[5?['KOLF7:EQNNY%Y;6UO*(WQ2LI)YCFY@UE3CAWA1DJ_]0+Q M_EI.-7L_'3DQ3:#-/6[*(R(K48ZP1+@[QV5DV,9G$2!E5_6K*%*";)5ZL8Y@ M*4IC;`-+!K=O<2^462!IPKE-#Z:+#=,^9[;=Y<-=<:1J\.ERN#&W!C+FNJ0, M*#T\5JF_U'%!_A'NA9`M;9LNVBLS8JP[E..!PU<,U5#NJJ%-DC*H.4TU4G(/ MZ=/V1L_'#=/8>T`^\*]AHX8*U]5XV-W,9HG/= M%/$R1N84(#FB@_9RXP_I:N<2%]PS?.#%XFDS6S"2[O(.'$WBZ15Y3$MKDSJ6:O MQZ9A(=<:+=GIEQ*`&,5K-)`&Q$O#C7KUL]VEZO'NBU;_`*2[&64C@)6\SAAF M',GB%TYT>W'\=I;]$NC_`*JV-6U.):>-*FIIW=_8MD+E3RZG;; MV[KAQ]T`>T@+/-[;PTS8F@R[EU@/.F0@9\@S.%2&MP'\1%>Q>ZXV\@*?RAP9 MCS/5`0D6=7R/#'EHV.F2M"344JWD'<5(14PDP=/6:,E'2+%5%8J:JA"G*.QA M#QU+:R-N6"88L(JJC:FY-/WCMZUW#ICC\%=1ES:\12N![Q10XP7W7^.'('E3 M8.)=+B[TVO,(_OD8TL\Q'P*-(LCS';A1"<2@)!G8'DFZ]J3;+*M!.U3]G8"E,(@&O>ZNFVH#I31I/I63]0.H>@=.M+BU;<+G^5/((VAN))[@ MI$4^^0-RHE8R*R67C*S:ZU"6N-6L2!H%VA$ST>WE&0RC.0,DK&.O9'1/6)*] M)TS")1\0U5DAN)X?2BR:PUFSO]-@UK,(K*>`2-,E&4#A45S4I@5V]C)1THW* M[C'[*1:G_P`+EBZ0=MS>[TK-U%$S?W#KR!!X&JK[>YMKIF>VD9(SM:X.'K!* M_2*R(#L*J8"'F`G*`A_=OJ;*>PJ9T\#26N>P.'(D+EUDV`W678=]AZ@V';SV M'?;PU!>@2H15-3?H4(?;P'H.4VP^`[#L([>`Z*6.6*4%T3FN:#0 MD$&AXTPYKB99$ANDRJ13`&_290@&V]W81`=M*A0=-"PY7O:'=A("YE.0X=1# ME.7RW*8#!O[FX"(:A4*9CV2#,PAS>T&JL'RXYWR227<4^DHQ8R+ M&O-6[Z>?KS4RP@XYG$LW3MBW<.UGTBG[TZI``@&'?PUXW-U%:6[IY02UO8*K M%MY[LTK8V@7&Z=9+O]OMVBH;2I+G`"E>9)HNA<->9>)N<.+I/*V(BS[.&AK9 M)4V5B+8Q:1=CC9B+:L'PB]8,Y"213:/F4BDLW4]:/K"&'P`0$-36UU!=0B>' M\+N/)6O8'4#1.I.A/U[0B?AFS%E'4S-R@'$5-*U*MQS:[CF`N!G\`I9B;7.8 MDLC?Q`M!0U#B(^:E4&%;*S]ME9%N^EHKV=BHXD$D$3@)Q45Z@`-BB(>5[?P6 M#&/F.#G4[^%3@K;U&ZL[3Z9&V&X2[S+G%H8`2:#B<>%>:F9CZ\0>1J-2\AUU M10*]>ZI7[A!^V`FD[&)LL2SF8[VE,BJI$W`-7I04*4QB@?<`$?/52US)&A[1 MB1["M@:5JMEJNDVVK6KJ6MW"V9E<*M>T.'L(]:[B"Z`CL"R0CL([`H01V#S' MS\@U$X<55MN('FC'L)I7`@X#B>/`*@.6XB``X1$1\@!4@B/H\``VH`@\"@N; M03D+N)C%``\Q$P!M^G<=17JYS6"KR`._!4`Y!#&HD$<5!KFN9G:06=HX>M=::W6H/I0\&QM59>321CD4AVL_%.)1,Z M>_K"GCT71W9#)[>^`2;AZ=>?FQG`.;7Q"HH]5TN6?X:*YMW7/[@D87?R@U]B M[.)B@&XF``#S$1``U.<.*KBYH!)(`"H4Y#`!BG*8H^0E,`@/Z!`=AU`$$5'! M0:]CQF801W&JXE52,82E43,8/,I3E$P>CQ`!W]&HJ5DL4A+8W-%: M<%Y-%Z*%UV^\1XS?0NYR_P`\>WCHBM5V>?NON#WT?Z9^Q7T18'N6W(+'G%OO MOVK-V5(&=L=&J='JS:6B:U#QT],.5+!@QM!L5$(V7>,6"J;5X^(90QU2"4@" M(#OL&L>FECL]2?^_]W:+LCYE)MQ:_%+-ID,30YL;6.=4V[`,) M"&\^T?6NJR%M;=S+NE\;\K<3<(W;'=&QU)XZDD9VH[>*&*40`H@!?"0G4=2@N[('X7MX8@FJ\S=Q=:NL>D: M]L'3KW3]&MLOG73F,9^`EQ-(RY@[![U3Q(JNRX1R;E?LE\@>0L;G?C;:LFXX MRW;&K^*SS3D#-S.*\S?R[YDO&V.1:*03P))*9*H^B7+M@X0D43;G4`2#JH#[ MC2[A[YP76SCQ\3573;^N[@^7#=NLG=&DS7FWKZZ#VWK&U):^1[A5U*6NN_ENU M']+4]'I[K7LF]+ZM(]%`LKZW6#'26FJQ_A<"P]^7$$?SU9#MG7)MOZQ%J<)IY9][L+3@:^BOK M*^HK./<4]QS@K,NJ#*MIW&W)S"CU>JR8J)"K&R,Y%'7ATY`J)U0:3M/MK=-- MVB(];=ZS.0VQBZ^<&LZ)=:3?76W]1%+B![F$>'`^'`CNHNK=?T^TW_LB[TYK MI8-NU/RT=X'[<7-^J6Q4S*[<0)&]S$7&OE`0(ZQO3+OR].D$AH8B[V?AN^Y=N=(MQ M66I'_6Z!YYC;S]YI:T?ST'B5CPQ[B2:X5X_[9'<0DA?DF,CYVMDIDUR?VD@G MI$Y*-&]=!Z"IBHHGFJ*2>&=8VQM#N,T M9>49#ZULVK3QLM=;0\<&2W`@M\7THQ$C'$"B:6)MX'\:C5FB]O8;,XM`S'T? ML6W^MER-\]5]!V#%5^D6D/QLX`P+*&0TK_\`!;0>-5V[B%@E3O`IW_E+RSME MXU748;F=P*O]ZQU%5>Y5R#RWAF?M(%2*#UJEZF;(= MT2M8>HO36[GMK:VG;'<6)X@D_PT4/+M8^,O(CNMWNP\I+]) MX]X\7O`^//&D7/SF%<73L%&?O:#E&)E7!?WFY`$$PV<'*8PE,/A MJWC-)JHFNYB(G0@AN:@%17V+`'ZKM;=77"]N]YW\]EMFZTNWN&CX@PL8^6R@ M?E!!_$W,0`/S!3C[0MDLJN>.:%&PK;LH9#X"5>+DS8>LV3EIB11;VX[E!(&U M0F9E$BSQL]8_O$RQ4_5@HU1:+JID64'?VTWSP+D0N+K/'(>W##'FMC]"]0OY MMS[DLM!N;RZZ;QQ$6LD[\_ZH.):^F)IFX2?.Y%8U[7FF8$4X@4I M3`@&O)7Y[_\`EIN/!7&5:@5E3J9TRI1W4<@`E]<_@82N2-T23$@#N;JE#QN^ MW^$!Z=>FKW'P^G-<_,_P#<0SDR<.G^*>"V&F=%Q^NW.H:.?6N(N3%I)K(*(;H+ M).G*-E>GV,(BBDU$?#IVM^I!NH/FE'X+=M`>^N/WK6W5"U_Y7W-NO<+7N&A; M;T_RH#^4RM>`ZGC1Y7MN5M^C+QVW>SE(VFS2L%5W%O=T/(,G$S3Z'6:5BI+L M*79E7#V-,*R0QT'$JJE-TJ&2Z>H"B.O:[F-Q:P$/+!P)KV`?8KAO?<$EWTEZ M?SONI(;)\WE3.C>8SY4#F0N]X4I1K?J4P*AB[M64ZL\@9SB)R8N^1D"14M#L&GM$8Q(!TEBJE.B/O@W,&O9QTYD3S;RE] MQD=@7$\L<*!;#L-/Z0Z=I^IZCL/6[FZUYND7AC:;ATE&>6[.0TM!-,2*GO.( M5M>VOVJ,`\M.%U#SA?L@\@('(MG?W:/5?U#*"S"(CU*[:)6$AWS&)>Q,@<5$ M&C-,RA1<`"IRCXEW#;RTG3(KJPCED+\YJ>)[U9NDO171M]]/[;L>%-%2,H#@\N;_NBT1ZR0+.5E&QP76F6C)+2XP,TX*K2CIP MDDNB+P$VS8QRHF4`TL-Q>R6D,!)]\@./=P/T\59M(W7N'7]G[,Z3Z-?7%O<: MP)I+NYS$/,7G7%8VN%2#E#J'MRK+RGV%N#3&"C$ZXMFFL7N*7CG[;*$E:>; M7/\`>;)PDY5?E3`/W&@=V=,?!%LF*(F`R8E,4!U,'A4RF,1(ZCG;; MI'5!I66WD=ICB3Y6(/:%BG0V[US:.X]4Z2;FN7W&I6P;XK\_:,?2#OG1W947DC(O&[3.2)&;5[(.WB#$G^H&6BF39H.%U46:8D3*7I3 M*4.DH!Y``!/IQ/Q5P,?ZCO\`N5)T)O9KGJIOJ-TLKX(;X,8T_@:T7-V`&]PI M1O\`#1;!Q=ND-O$-7=OX0NK\P=[PX%0PNWWB/&;Z%W.7^>/;QU,BM5V>?NON M#WT?Z9^Q7T18[@Q;?'O]0A,7Q_C.WN\8K8O3:?QN]I*@+%Z=NKPU81:N.O>:0;/77.6,0 M92[1D`$1='(PC*QQJ.;JXBN% M*8XJ-7`>N\FNV-Q#ON=[!Q:R)D2UY^S-2'R.#::TD'5@Q_B>%B)95Y:IYA'- MY1Y"2:Z3XR#%HL@HN4J;<'()[GZ::S?-9PNK"\E[\U!Q``ICV?2O?B/2^SWG MT?Z?76XY=&N+G4-2U`2-M8\]8[?+[SG`#W7U)R@@GB3045G>9.1,E]Y"ZX,Q M7@KA?E7%LW3+)*KWC,66Z\6OIUZMR#9LRDHEU8TV)6I(>,$IW@ME%U':[M%( MK=N`BH8::^B?JDL;O+J"\-*;FO;< M?K!HQ,0X.-.-*\>SCP"WKTBWE\/(-O:F?]*\_IDF@!I6E>^E/&BE)W">&G). M&YVYKQ5@G'U]=X9YPSF)9>W3];I\[*TZ+4EKI&S,\E.V*.CG$77"U^^1SN4< M>O4()&C@#"'2(:XFNK21]^Z*UB<;::A<[D'#CX+0W5CIYO6'JG?Z=M2UF?MK M7GP.G!?F(P`!J3RHLX7=1XHI9"[:5HP]C.KOYR3PG!X\GL;UF!8.9 M&8>)8V,QA3QT1'L$5W;Z0>T]=Z0B293'6.;I\1'5SO[=TMD88!69@JWQ'!=% M];=A.UKI$[0=%C+[W3&0/M6@5<3"!$0*<28G.]-"H&=F?CAF#(V2^2'*CEI1 M[C"VV>HE9P'6VE^JTQ495]`#58N'M,@QC)IHR>>R#5H&)CRNBEV44]H\>H3Z M\-*@O'-<^_;20BG8:46M/E[V?N;5-;U;>F^[:2&^EMF64/F@M=DR9'9:]C0& M^E?NXZRG)'LW3F3,)Y!X_97Y#<1[7>):ZX?R?@F$++:-@1`X*.UW[J^7B6]VYJVE7.I M;*N+HR6]S:^_+'6@]YH[AB.W$$@JO)_(W)ON^1-:C'Y5LPP MQG`EPX^"AO35=W]>_)V9M;2;G3MK?$,DNKNY;D\QK3P:"..)PKF)'#@5ZVG< M`:-DSNJ\C\>Y;P3/6/CC#<8*/2*':+)69QM7$Y2L4;#U3B7]2N_LZ$>%RC63 M%T!5FJXKI*)K>&PG;6CM7CIG2>RU;K3J^DZWIKYMF M,T2*VBF>"&YXHK6-A8[AYC0WU@U5]^!%)Y@<,6SNPV@94'+&X_O?ERD\>&%5 M!+MFN"W,N]REMR[.WQE*4S$'1RV\A+GN-0#C4G[UK[HWO#35YH]DXNT5-6H5 MC&\\XLD%*WC'B:"T#-2!8M:$:3=6<*&1D&PJ^L25#;8!\-0`G&L/O!;R$&-O M`=QP59K.M[CT/K?'U-9H&JW6ERZ1$!'&WWHW20AI:<*5:ZM1QK4JX6>I+F%W MA9S&^$8CC%D;BUQ4JU[@KCEVZ9P;#`VF?P0D8Z;,W+H6T4]<%8MV:2 MP*/%2K.5TDTBD-4!]SJC_)\HQVS78UXDA7O=;>H77>_M-LQ:-WB!^':['N.`'L M^I>G7?;&I:_U`VIM>R@N':+"YIED8TN8T9PQH)I0$-;SY'N7:>]CA_-M=R1Q M4YH\8*G;;)EK%\M8Z!)!2JQ+VV3;14G'OI6MR3N'A&SIVM%-%',JT6,8OJR^ MW$*(^(:GUB*\A++BQ;5[00[P/#[55_,3MK=`UK1M_;#MGR[@MG/@>6-J2US0 M8B1_>DQ\%VKA#PRG<;]HO-=+N5:F6>7N2.,\Q7^YPTQ'O6]J)*S]5EH^DUV3 MCE4"R"4PVBHUJ=5J8GKB/':H;=0COZ:=8&+3W1R"DL@+CZ>U7;I_T\N])Z$Z MAI>IQ.;N+5;:ZFG;0YS(YKLK3WBF`[UAI9T+D"WX%\#4'G'K.,Z^P9S6R-;I MBGL\47%>P.:.0*7>6[E.'7A!71CY9=R[9MW"Z9&ZBY3DZA$IM6\03,M&?I.> MYLG`=AIC[/:N>O\`9]W/Z7[5@?I%_-/I6M3.DB$;LSHQ)$X8$<"`14BA)6;1 M[SE6Y.8\Y`8/,&]W.LN;<]:S#''LU"5>1 M?6FQ2,W&-ECOX-249-VWMZ:3@_J3"!BF$H#X:H[.\N[2Q8QMM+YHJ!AA6I6N M>F/4?=.PMAP[5EVMK%SJD3I2UV5PB)>XY"?=)RU(J/:%^*S\,.65AXT=QWF5 MR/H3I+D=R:H]9KU&PM2VCBSV.M4]M>J5(+,58>"+*N/;2Q\&Q;MF9%'#I)JP M447Z5#F*622PN76]Q=3X3R1D`#U@)-T[WMJFT=U;^W;:-.[-9MQ'#9LQ=$P% MM"`*G.`,&XG"IXA=4J?#?E53^+?;NYJ8"QG+O.0?%F-OC#(.%+5'R%?MMDHR MF4;Y-L$6U=E46$DJZ_=-AD&J[8H$>*,Y$BKKIMW2KFWS$DQC6<:R`3&]H=HMB[%_S M/5`(F"Z"_<2`(9,W93[5N>VZ_P`5VZ&Q9H&LNW$XAIM_*(#3S/F$4('@!R47 MLO<:#Y+&X8T^E#[%A&O[*W!U3ZV9]Q07MAM M/3+(FU>#3,X4]X'A4N)X$DAH"]+R(X79!X/\Q.$O)CC<\Y)QHR/"(K:E6?RQNMXH5J@[;HCUE$P`/G-8?`WK);)I) M)H034TYJFW9T[U7IQU$V]O?:QU'47R7!M[ILKC*_(X4/O?E&1S@*X##L5L.- M^?,H<'>9/<+M%AX;9\WS;BJ2N-L73CF/-'P5[O[\LC[>_8H,W[&5:V M!$[=9L=0ABE$=]A`=4MN^XM;J:62VD<'O)J!@>]8_L_<&X>G?43=NI3;8:RO@Q5*SS5:_@K,4" M-*ZVV3NF?=VC MG5[C3KG396REODS_`-0T`Q-!3%=+NP?_`)#N,Q=QV^9?SE#?_P!W_7/MX^'Z MO#4U?>JLLHZG'WLU:^FM/L5KNSS]U]P>^C_3/V*^I5,LDNP>X'B.X^'I]W]. MG.O-1J4V#W`T4.'!5\O+1%Q`A0$1`I0$1W$0``$1]T1`/$=1J3Q*$YJ9L:<. MY5$I3!L8`,'N"`"'AY>`Z@0#Q2M."L;R9P_%\@N/F:L'3"*"T?EK%UYH"@+@ M7I37LM3W!P)]E5 M;M7LAJ>EW&GN%1+$X4[Z8>VB^/\`S<)*5J9F:W.-S,YNM3$G7)EF0,O(_P"G*P2#PD`.'C1<+W<#[2Y?:R#W MVO=7UX"J]7JL(!%#B"J9>=LX<-'*#MHX<-';99%RU=M%E6SMJZ;J%7;.VKE$ MQ%F[IJN0JB:A!`Z9R@8H@(`.I'V\4T;H7AGEO86N!`H6]A!P([`>=%.R1T3F MR-)!8:BG(]R^D3V)>ZLSY\8,)B?*\XW#E=@Z&CF5X24V:FR=2$3!&5_*D6D* MO2Z?N/5$;3Z29=F\B)5=BIND@#A;JWT^FVAK0U'3F_\`ZY=DN;VQO-26=PK4 MMY4PY+K7IYO.'7ZM:C6R:#U M*@E*/B)2B/NB`#_;Z?[=1J1P0@.%'`$5KZ5RV#SV\=0H!P4502@/B(`(^Z(` M.G=R2II3DG27;;I#;W-@V\]_+].E2H96TI04^A^O%4$A!WW(4=_//Z?#^ MS4*`4H.'#N4>(R_E/):ITE#;WI?#?;P#PW'<=O.P;^'EX[;^&VH*-2J[!N([!N(``CMXB`;B`"/GL`F']>B5 M-*K_BZ0W_7MOZ-*FE.2F7+_`*=01*E`#108"M?3VKEHH MJ@@`^(@`^CQ`-$4+KL`?:(\9@V#;YEW.7PV\/_/+MXC_`,^E5"@XXK MY=O?.X]'XX=SKDG`-&`LJQE";89YJ/00$VRD=E-!26G"-R%Z2@FRNS>5;AY[ M`GMX>GOSI%N`:_L>S]!UV]V]J4>IV1/F-<"X#\[0<6GM!'V MKZCO;NY^XD[B/'6NYPQFX)'3::C>NY3QXY7]=-8QR&@R;N9>LR(B1([N.6!7 MVF,?`0J;]@H10-C^L(3Y\[PVG?[,UZ71[\/+:ET;_P`KV-01``$-]]]M@]._GOKREC<^F3B#[.:D>_(VM,2M83^H,[3 MG(7GI8N.^6.+%,@[ED.CQ=OQ[D*-EK95J2*M+>.FMBJXTIK3>G_`/F7/_IG_"G_`!)O M#_*B_G;_`(D_].-W;/1@"F`/H$,\8D`0'T"`A9]P$!U!W7GI^1B^Y(_^6?\` M"IF=)=XM<"(X@?[3?\2GIVZ^V9WR^W+R'A,TXTP)4IZL2((067,6N^1.+&4! MDNE&7]:NR<=%F5;M++#F.9Q$2(I*'9NMRB!D%5DS8/U`Z@=,=[Z%\%/<3MU. M,$Q$PXAU#EJX-K2O$/#T\L%T(S$8]B]KJ"@FB)HB:(FB)HB:(FB)HB:(FB)HB:( MFB)HB:(FB)HB:(FB*%UV^\1XS?0NYR_SQ[>.B+'_`-JSF/BFB=NGA]39JD\J MY"6K6$ZO#R+VF\'.9^1*HZ=LBN$EEJ_>J!@6S4FUQ1SANB^BY!XR<%]\DJ?_P!6C1$^?GA7XON:/Y=//_ZM&B)\_/"OQ? M?_U:-$3Y^>%?B^YH_ET\_P#ZM&B)\_/"OQ??\`]6C1%0>>>%?B^YH_ MET\_OJT:)AS0>>6%?3C[FC^73S_^K1I@I7`$8\%Q^?CA/XO^:/Y=7/[ZM&HU M\%+D9V^U/GXX3^+_`)H_EU<_OJT:5\$R,[?:GS\L*?%_S1_+JY_?5HU*ZA%# M2BB&M!J#BGS\L)[_`/E_S1W_`/YU<_OJT:\R(?.#G9?-IA7CZEZ$FE#P5?GY M84V_\ON:.WA_^NGG_P#5IUZ4.;-C50;@*-X+E\_/"OQ??_`-6C443Y M^>%?B^YH_ET\_P#ZM&B)\_/"OQ??\`]6C1$^?GA7XON:/Y=//_`.K1 MHB?/SPK\7W-'\NGG_P#5HT1/GYX5^+[FC^73S_\`JT:(GS\\*_%]S1_+IY__ M`%:-$3Y^>%?B^YH_ET\__JT:(GS\\*_%]S1_+IY__5HT1/GYX5^+[FC^73S_ M`/JT:(GS\\*_%]S1_+IY_P#U:-$3Y^>%?B^YH_ET\_\`ZM&B)\_/"OQ??_`-6C1$^?GA7XON:/Y=//_P"K1HB?/SPK\7W-'\NGG_\`5HT1/GYX5^+[ MFC^73S_^K1HB?/SPK\7W-'\NGG_]6C1$^?GA7XON:/Y=//\`^K1HB?/SPK\7 MW-'\NGG_`/5HT1/GYX5^+[FC^73S_P#JT:(HC7#FOB%?GEQWLA*+RZ*PBN(W M,N#=-5N!'.%M/JO)_,G!!^Q7C:LXX]I6>8B&Z-: GRAPHIC 5 g45280img_001.jpg GRAPHIC begin 644 g45280img_001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`;@#D`P$1``(1`0,1`?_$`+T```$$`04!```````` M```````'"`D*!@$#!`4+`@$!```'`0$```````````````$"`P0&!P@%"1`` M``8!`P,#`@,%!`@&`P```0(#!`4&!P`1""$2"3$3%$$B43(587$C%@KP4A<8 M@9&AL4(S0R71>1.$^,E#D\H9ZRA3<4 MT.*((.;#<)EI&(JK@4Y_@QC50QY":DU2E_AM&:*[DX^A!#J'H6FS5E_J_E;2 MRJHK!@0D$A/^8C!,LR52PCS[EM>2A/!)(!5Y#,\L(9S@;F=F;FQWQR7.<8_DCR0B']7>L@E,P,AG.+&U75ZZ$/,,E%N,_4KTD M\I#.)+&P+`BD1=4KA8J9"J+%3*E[QR$(5184B&,1/W%!$>T.A0$`UX4>^01B MG3?_`$?C^[KI$(P*UK9%*L?^2$*0X(5D8Q"VI[8&??(?],AUH=D^ M(DS$OJ($,IOZ`.IQ/3/A'EUPN227*/Y?3(2ZBG4X_P#!Z?IC#=K->^;L"HLK M#.(!C"<##\CH/;L.PCM(5Z,1B>( M&<8U45^_Z7\ZGI**I8!EI9=4%GS+VE`'.1G]<(+8?(!F/%8J&SCX^.5=>8)= MIG-CQ6WHV>*TV3`@^\L9:CS2,L5%(P;E]QJ0YR]=@]-2%_+T*`YQCE5W+O\` M:05WS;-R8:&;C*D5`PQ)DTM9RQE+ZXW\;>7S@+DB3"O'S>UQK9_<507K.8J_ M/8QEF;@A@3%%VK8V"42@J0X"`@+K?\0U,764'UK2/,R^V)[/WQ[?W2I%(Y6_ M+/DRE4H-.?X#(OXUPY M:J@(#OT,.@6E:>H@@H/$9>_*-H4EPH+FW\Q;7FGZDD1D.X>N_30 M$'(Q<$@"9R@TU)G*8G$\VW1H_#$>&6,F@SDK"NR4 M!!U9+,[)[RM=H<,X,4'+P2&475V;MRG5,/9F>R=@W#?-R%+3*Z%$@ZG'S@D` M8D3RGPE/QC#]V[OHMLTH7_4KEX);&/*K7E%"/(>S6*@JB#..@UB`0\?#K$,N]3(5S)*+=Y$M9_N M[=MGVG0':&Q&T-.($JJK3\;CF2I*GQ2`">&,L`GC%HMM8*DW^)#M)NMH"@F#=O%LY*,2,@W9E*D"+>/11.,'H)IE;N:1FR[+-6YT14%$X05UD+?7E2$ M%3J0S3M.``!@,&A],_&/%26->1,:U[EC8\Y*8XCZ=./6V^X-6.3\8!#-OE[!L!W44!?J(ZM'4U6O6V MH=*67C&-UUE[E6:;NW;DU<8DSWOH+'B[#6Y1I+0S],Q0,`HOF2RJ!C@4=C)B8%"#T,!1 M#7I(#;HUH(*8W?17"BOE.BYV5UJJMCB9A3:P0/$R/#B(1//O#3C/R=B%(G-6 M'J7<3J(*)-IU6*2CK7&'4WV7C+3%?#G&:Q#?<&RXE$?S`8-P&TJ*:EJA)8!^ M^,8W1V_V3N]@TM\M[+CJA+JMI"5CQ"DXS\YQ`GG7Q!D!(`@#"2:)N3"(=JBI@`->6JAJ*1&JE4>B MG$)]LXYOW%V%WMLA"[OVDN]4I+1U"E=7/#,@8"<_?',X=^>R3C;(CB#GE2PI MEACY!.N2&5X*)'+'[8L6O(CK1=UMRJ%FO6^@T;\M"DF:1/(DC"4*:@L"Q0,`&(`?0X"`B`F,7Z ME*(;=NIB"(]%Q'20EQMS4PKZXY(>G74D5B`#).4&D0@TA!I"#2$&D(-(0:0@ MTA!I"#2$&D(-(0:0@U`D)$S$1*>,-JY<1N6GZC:G8Z@CR`L6Q MDRR5DFW*J;*OU6%(<=EIBP2RZ3=(-A`G>)S?84PA?V2SU^XKBS::"?S*U8D< MOX1Y]WNE+:+W[N=S=%P!5;65$(2?APF!++Z3B^4F@ MDF7L(F0I``I2E(0"%*0A0*0A2EV`I"%`````"A].FN8`%+3^:2HDSQC?>ALH MZDSHF!4@J258B'"VS@X'7#WSM/=`%C@`G^[[A] M=]5!*8.$P,,(\VXVJVUS*[DZG\?RK,Q0`AB`R0'LZ`)&<-6,J#81.9)D9(5P(43,4'(%*RE3H#(&/[/#W*F6I@WDX&QP;U% M]'2;-R3O*=!=(QB@)1$2J)&V.DGN]&FZVA2'[< MX@%*DF

)(X\QPC$<6.YMK;=W;:S9MQTS;S#P MF-0Q2K(*!S!$\Y^<5.LO4[E'X*\_Q%IPO9YK('%+),LB9.!M1CFK,XX(*CN2 MI5K:HB#:"OS*.0.HPFFI4C.D`$RA5!*HF'D/MU-M6E;2B:92I2X2R/CEQCB' M<-+O+]M&[$UUC<=J]AOJQ;))0`7L3Q+.O\E:E$KK-E6B2;9C MEJ,CT%5BU.R)D,F16;[2F",D#_Q$U!!)43)&^WRKE;45K)T>EY()!CG/OOV6 MH-^6=RZV5EMK<[8*RM(DI\)'I;.,LP9$`$S,R<(@.\8W/-?!L\[X=1X2CF#LQW0J-M7\]N=]N+=L-0>@I+ID*5:B4B2L")X3).$A*4A M%@[Q!\G93,E2Y"86DKA)Y(B^+>6']!QSDN25.[D+KB%V[F4:`K+R9O<++R\. MU@U6PO!,)WC8J*HB;N[AR6A<6]@LZC.4_".L>R.^?]1VZZ6MUU=:S;*HI;=5 M+U-F>D#2!.4O$XYX1*Y$9!JDU:)ZE-)E`MNK(-7$Q7'13LIA&-?>\5C,HLG( M)K/(%\JBHFB]1`SN+@L1 M,Q3""\F`@`"4!UU3V%VPW14-1O"K$_0HM@C\`.*IXRE(\.$<[]W[X[4W=O;] M$2$)3-4CF2)G#W"+7?C(XEQ?"GA-@G!+5HS1L<;4&-JR0^03*169R3<4B3MO M?KFW`[@6C]V#),Y@W]ALF'TVUSWO6]/;EW-57.I5K;+JPWC,!`40DCV8^V-P M[3M+-GV[34E,-"E-(6HRQ*E)!4#[8?S_`,6WX_[-8WP\HR9*,"KZ90F=IRM7 M:,].G=0D*U#"JFFWM<@S64JJIE$B'$KN9:%8S:(G(6QQZ,M`S$9-13D@';240_:2;)'586V699X'[#&"9-C)%A>3.,KE+2,OB M%[)F7*BTG'46K9:S*12)Q,D@A?:PDLD_2)_"-,-A.`^X<^_D-5"J6J-`N:S@ M=67Q<)8\N<<>]HKU<>U_=.L[3W1QPV>J6I=(5S](49IESF)2RP`BTP(=0Z&W M`=^GT'ZA^W?7J@A2]!E*4X[9_+!U+4#))3/W9BH8/;7CY=%/N$!*)T3J$$=C#J/2U(4AR2]0 M,N$C*,)W_LZCWGM.IL-1I*5-J4A4IE*@"4R&''#.*K_@CY"6G"?+^T\7[4]< MHUW+K>?AU8-902LXC+./$'1D7#5%4`*DK(1T:]8J=H%%4"([@/:76,6EYU%6 MJD?$INT6C5+MW'[EW1T42E#T^XP:R0K!.H2"#EC'T8J'VJ8E M=2IMAD<5J"1*7C#!L_>4C@WQZ3W6U4I56W!MZJUZ0A@=5 M>K#\((Y@9B<4MO(-:F&5L_6CD75L$9"P7CK.4@O/U%C?V`1XV^0CT$6-OM\. MT*T00;MYUXNDNX03,N4BZYC>X?N$0QRYN4Z'$N)!Q,\I3\H^;G>BH9W!N8[P MMUM>MEIN`6?S,%/.MR_,`TC3F))$\?Q1:=\!S;&*G!&+E*-`H1%P7G MYC&5?6"XP[E/]-?JJ''N3CBU5\R(T1``32(!@+OU$??M:A\MU!]/[([A_;`U M9G>V#3]H;"*GK$5&,RXH`8DR$L"<,<9PJGEIAK%CS`S?F+B::"H9XXMS$39Z MQ841$I;#2Y^>BH6\8WL[<@E),U&PLWB:QVJ_QQ)S_%8[&%RM@*R:&?N:<-;Y-NU>AG:':=UH`-O,6_IRYE8$SAXJCD:V.KW!W!34.'6IQXZ9\IF?TY M1ZE(`&P=``0#\`#;UZ!U'8.OIOK@1!)0"K,@1UV``)#(0"`[;_0-3Q42H`2, M<9RD1RBJW,"8D6()5"F3*JFHEL(&243'[#IJ%W`0'H(:F20,3B(DA4'["* MD53`("/RFBX#L&X#MJ(E+'.,2K]G66J=4Y3!=&XK\=))IWVK203";+\;N3M8 M[CXWYOWL[5(W.+-,+;L0W_D?3FN M/%&%@J%/M%*IR9&DY8[C&MKY'*V&S2'M-*^FHH]58J)BFT7*4I1-L.L?=2K] M:"1GI0?9CGX1R3W!=W(]W]LU#2O4]5N&E2@J6ELMI(5*25"9^'B9Y'PB?8\A MY81-W!7."6P[B!"V?-G3<=_K";B`:]LS"]26P?:8ZK><[M-NZZ=-I-/+U`J7 M-)G@#Z//C&/R#+R[3"CLJ=JX'X\8)-053?H0.8+P[1<(?Q5!.D^>P3<4EB;] MQC;>T`=-QZZE47SB$A*9<\(LJH]YTMJ?ZMG99""9G61(`DG^F<)#&*@?'JL9 M3S_Y'H.$I.1U*5DN[YYN4JKES'$(9DVKSM*5L,G9KM4H-510C>.%LS<*-FZZ MH$]I8"&-N/7$J5TU5T45G3,G'[)1\\ME4NX]T]XDL4-<*2[KKJC6_3SDF:EG M4F6F0,_3X2BS^IX2Z%?WA93DCRQY6\BU3#[CB.LU]_EZ"65$>U51*-CR/E6X M'*&W:57;;T_#60MV_1@M:BC@.'WQVVC]N]'(Q6K# MA#UL(^.'A1QV4:O,8\>*`PF6?8HE9Y^.&YVD%TP#9PE-VHTHZ:+@)>X!1]H` M-Z`&JZ*>G;4)-S5SC8VW>TW;[:;@?M-JIS4ITR>=`6L:3.*5);F#^8&$9DNR+I$[!,E"OU:S#QX'VV%)`SY@L!"_E$`-TZ:\C<"J M=#(*DR(G[/&.5_WDUU$^;);7"V*MOJK6`)`-DHD0`..D^.$.H_IXXEW5>'66 M;Y9G*<16;+FB7D8MU)N$F$U7;T_,A]WIU+J`5`2,L#*4A/.>)$ M6&^%?'H.*W&+$&!C/4Y1[0:DS:3.<.EU-&;0: M0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(8!Y4LG.L/^.7F7?F"QFS^-P/=XB-<) M]QCIR-L8EJ#,Q/;$IP5^5/E[=O00W'H&LDV?1BOW10TAR54)_P##ZONC'=VU M9H=MUE4,TLGZR$_?'G7^&CVF7E&X.BJJ1)$F<(AL4R@E33*HK`335L0IC"'> M9=50I0V]3F``UVKW63_^`NC8S0T@>XICESM^L#>E"L_C63CXSCU3_77`31FT MD_X1]D=C'.->NPAMT'_?JI$J_@,OBAL.2(#D)67[FU82L-;N;51R#F3Q+E=R MZ8P[X%!W6/2\@0S9W,U-Z<`V(W>M9*/$?0$`WU53G)&4.+\P\:)0R@HJSMSJ3VW8G M7-N($/&99QVC8JV=LH`;E%X5DK]#D(/34-7L2.>,8F_W(H;*LM;MI*NW._S] M(+0?)QC6L^U(C3-WDRX@XBP9.YM8YCH>2F""1V=;J^/K7$6*Q7&T+`9.-KL? M','*CMM[[D`!=PL5-%JF!CG$.W8;:IJ4=.;2@2,I9_3SB339NW=O.[A9K M67G6$D-,)(UK41@"DR./C]L1^^*7BGEB]Y@R%Y,N54,O&90S.I(+XII[U,Y' M58J=B(W2&==,U!*K%`X@6[>,BFRQ2JIQY#*F`!6`-6MOI7%.&J?P=,QCR$:Q M[,[+N5[O=3W9W@-=_K)J8;E_3:Q*!+@0#])18.*4W:`=H@.P[`/42_L`=>DI MD8VB4G)22$: MA(L5F<_>#H@50R;*LL'(BF/E$8_]/WPLFXI6S1C7JH!=[VFDN4BA6CP[8(YJJ(B50"N%"_:)1'S;31:__`)*A(Y#Z>4:5 M_:EVY>MZJCN#?FE-U+R.FP%).+\W;O;+77K[G3K7/!#1ZBCIQ(DGPBEOS/SKD7R*< MP;7<\>TZXVU*5.2KXBHM?AWL[96E"KH"C'J##QR3E5-S(+**2#LP@4A#N.TX M@!-]8=7E^[.EQ@:DIX#CX1\V>Y6Z*[O%W&J;CMQBJJF5`-LMA)D`)\L`,_OB M4+#7C2\GG);%F.,-9@NS?BQQ];136+WIYP:ESXF9F1/C#\TP``$"[]OVB`#Z`':``!?P*`!Z?35ZYP MC92`4DMJ!UC,\#Y>4;FJ<5(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#0?%[/X1* MY@W,9SB#W^HFG7$)XG>0Q$D`5_7IO%=>5-[ADQ10?9*K:IG!0+^3:^<8+W,)1M"J4"=.A,^1]0./NCSL^-64W.# M.1>#,RM^\%<99@H%Y,)3@F86D'9HYW(E*H*:OM&4CBK%[NT1_=KN#<]O3==J M5]O0D*=6V>&,/:2D>Y M1.51)PQ?MTG35PD<@B4Z:J*Y3%$.@@(:^;+K*Z=Q3#@TN(44D&246(QK,,,FN*:*A4S$.JN MX8QJ"RAS`!06<);AUWV#?4R$-6O]CYCY$:N MJ_B7%>,\01CXJC97(F=+(A>GT>U4*7O-PU,6BAIJ-O+JU:@L$>"`52]HAJ5'\+_%=>7M>0^1Z#OD MIE:]%*I9[+.1[+'-68N#!W%&F43'/Z!&5XB`B)2*&5<+[=1.)A,8?-_3$\AKLC&QGR&WLKK$93Z\PW2+[(`'<)^A2^NP:E_3F`=1==2YR# MBI2\IQ?O=BMHG4Y05EZH6P,DU]2EM)'\I4],`<@99"40Y<^2+I-M6\0T&]H7UA%S+HQ&H%M-HCFIN\#*EV,R8'6?`(`/MD*`F&U= M6VE6BF6M;WF3AYQSKO\`?HMJ.FU;6W5?;GN/7I12M=1T),CZE/@*U)3@"G69 ME0)G+#:PCX8>8',OW#6?$=#>/";X],-5.7R3R/SGF9Y5(9,%9>>R%D MR-@V`B1`2"AWL8,'[YVY.`>TW0,HN8=B$*/0-2&AHZ8E3SBE'B2H_P!L27+L M)VWVO;S=]W7FX+H$CU+J*@C7X2F,>$@)F40:WC%...9^8H[!'C&XJK15"K,B MF,KEFRO;0[L,T0IEFQK%>)V?DGT/0:*D#GO;L@(60>=@&$@'`B1;-U#->L-4 M@(2C$D\0<,?='+=UVK9>XU\3MOM':5-T#2SKK5E:PX%>G%2R0`)$X`9XSBUM MXXO&UCK@927+DCDEUS==(R/1R-D5PB!$O;;?QR5>GMC![\75&CM0Y_XAC.7B MO\5ROB>S\HS]@"PM MDQ+-O`76[#"P9Y(KR:ID"@0WN+BLZ*!2#V[E`P[]-M;&[1KZ/<2W*'XG5S]K M2S]T85W&:#VS:T*PTMIE_P`Z1]\>:8H4JY5"GW`@]R1B@(AW$$=C@(^H"<`V M';7?@=4TVMQ`"NH)$'+ZHXP233O#1C(SCU%?"1R4)R@\;W'2V.98LK:\?UG_ M``6OXG,`NT++C`"5UL9T`G.<%7E;1CW(&'_F%7`VOGKW(LB]O;KJZ985^:Z7 M4$C`]4ZR!(#`$F7A*.V-D7A-YVTQ4.:14(0E!"?\(`!,R3,C'SG$LH#OK"") M8<8RW[(^1(!A`3;CL.X;B.V^_38-^FP=-0!E".(\,Z0:J_IR#=P[#L]E!RK\ M=(VZI?<[E>Q3;9(3&#IZ@`?74=42K0E8D?X_;.&U7N#Y>SSU=O0;S@6CPBJ1 MR(R&@![4@Z%,FH'?^(=-0"2/Q1B%R8WPXZ?TYVVH2 M?^H4O%8\@5Z#[4F&_P!P\?+K-P')R7Y4\CLL0JAS?(H58L<-A?'#I$IC@#5] M7L:Q$3*2+,Q!V$KM^N(_C]-6CE&AQWJ+4H^$\(QFX=L57YL'>%VN%:C\3;:T MLM>`DTA"O/U8PN>(.,O$KBE&E3Q1C7%N*R)I]B\ZFUAFTVYZ&*=5[:9M1Q.N M5C"?M,8[DPFW]/0-73+#3/J0@3YQD.W]K[`VBUIMU+24ZDC^JX9N'+#J.**C MP,IQV%KY?\>*A[B)[\G:I<2J'1@L;0%CRA/NU2B?_P!NC%T**GU/?.*8@'?V M!OZB&JQ4LIPRY1=R2.8>5GZ;BRF1K8Y2@H]CJ.>7<7:5=%(?N2(N@@4PD'N3$.FK<&L& M24S\?X3C!+WO3N%>PJAV%97`PYA\S5*Z:4CGTB4+P\SY0W2O^([(W(FU-,D> M2SD=9\\S+)^9W!XGQQ*/ZEB:M%4[!,W;HHM&;OY1=PHJJH/J8 M=5T-M-)TM)`2?#Z3CH&P[``Z]O[= M3%I8SE***W"ALNK;<"`9'TGZ2C=`P"&X;B&V^X`(ATZ"`"&^X@/KJD#JRBH# MJQ3B)9QM$734$Q2=QA*`B(=H[]-M]@]1VW#T_'513:DB9E$P!,I@B?/"7GRG MPYQ&?YE*`?)GC"YHUE!FF[?-\,2]L8I*HE4,+FA/XZYD4;D,=(OOI)0I^T1' M[3"`[?00!Z;`/:(:^B-$V5,I0YF4`CR.,<3.MD* M4[^$*E%H[^EWYI%Q+R7N_#^VR14:7R-C%+/0S.G2*#2/R]28U8ZT>V(N_ M<:BBJEVD^]9U')``")@USQ^X+;(K+>UN&G1.JHQ)W_(9:2G^8@%,^0G&[>T- M\Z5P7:'U22ZF:.4Y83]GVQ?D*Y3VV-N`AN&W;ON`==PV_P"';Z]-FP:!:B9$*]T72:%AG%IEM!EDF0^T&.7L4>T>S\-A$!'M,/H/XCM MJ<.34I`S$5"&W3-PI&&8.?DH2!]T:IB4NX&$>XHB`F$NP=>OV^OJ`]=2J.OU M#X?X1`I#0#SA,E'#49GER'*-?<*!AW-OOMT#;<.H^NWT'0(*AA$$NIZO3Z@4 M3PY>),?9C%)U,.W[^GKJ61F!Q,5@H%?3R5X\?*/DRI2^H'`?P[![O]7]NFI2 M0%:.,H@M6@Z0"HC^43@!4@B)0W$0*)A`"B([`(AOV@'=U$!VZ==M3Z3GPG`J MD0""-4Y&6&$IX^V/E-=-7?M$0V$0$#E$NVPB'7Z==M2JFDRD21RQB1MU+C:7 M`%!*P2)B1P_OC<[PV$1W``^HAL'[_P!VI9FZ(%*@)R,:=P;=P;C]=@#J/78=@^NPZJ:#%)3H2#,*U#A+'V"`3D`0 M`3``B&X`/UWU34K29$&?E!3S2?B4`H\#G[HU$0`-Q_;T^H[?@&IA,^^)@M)( M&1)PC0#E$>WJ`[`.XAL'7]NIR@@3X0*D`Z0H%4Y2!Q]T:&4*4X)B!NX?00*( ME_\`5HEM2DZQ*43G2!-2D@\B&CW2THM%D(L8%2*B78=^@! MKR:JI<^9%(THI*@!/'/GA]L<:]TG]VWGOE3[/LMYH#4F9 MPGF/.-FLD\;+24 MXSE%']6*F+5PZ=$=M'13AV'$-5&>NPO0\LK!&?E]/;%M1;Q[A=L.XS&R+I=! M?*&II%.`F94#(RS*B)<82#A!B3*/D]97K->4?(_E7&&97-UFD8;#^.;86*6K MD2R(@]C7B=/5L$6*-?\`DO.QJFP:`!46XE66%41V@TR[4.EX+S.`CR=A6:K[ MU-5.X;KN>KHKFFJ6AJ@:6$].1])(*A,<)2X1E/+2?Y(QW)KBYXXLF\U[MCRA MIT.*LE^Y-R#Y"G3>3)VPKV9^HZ>R:+^+2!C$%B&\/&-7+SL!TPSH].HCKZ3VBL^8M5/4SGJITD>.`CGZZ-="K>I>3Q^V M.[Q_>[7BR\T[)%!F%ZY>:!986Y5&>:"4KB*L=?>HRD8[()]P,!7:`=Y/^H41 M(/0PAJIK%P$Y=5/ MGUQ#QGG^K/"QTE;:\O!9#BXQ7L?4O)L.@6*N4&&X>\W5828& MK#C949G0#/2)FW=J5)9O%?5A2E),CH&F1/A,QF<;Y"N0^796X0\D]J=9S2XJ\O^/\GQ>SY/Q+Z4QV8;*TN&-LH%8MW#CXE6L[9%(2NW1&BG MM%'WTS&(*7>"O:0T_P`U6J,BF1X1Z%F[N/M7P[1W];C;KOT%J8(5.F>*0)(2 ML@'61BG`B0/M:1C7S!\M\IX\R+FFA;V:$O&E@FXR,F MI'0$Q7V[]Z9K$&(Y4[$U"D(([B&VH"NK2G4I`TC/R$8!;^^^[[M;:J\V[;;" M[-;ZEQMQT/$^ALJ!4!T\Y))Q,.BS1Y7(FH<8.*7)[%F.$;K6^3.4J]CG]!LL M^M7I"G'D3R3.:%PLQCY!%[*PDI$KH>W]B2H$`P&#?;5PY7L(:0Z)R7*,YO7> MRWV_9UCW10T?6;NU8ED()ETR2041:P?E>YGEQM$9]M?C2N;OCY(UUO;U;W0, MEQ]@D"59R5-PG8T(=>((N:+(Q$RI_=(C[90W.8I=Q""*PMC5I(2>./\`=&E: M/OMW$5:&MT5^U%_Z96C4XZA1U);!^.6C$3B4>`Y;XQRGQ&G^5F+[`1]1B8NN M5S:NWB94'D1(UF%D7#Z%F6PG$6DM#R3,4%TQW#O*`D$Q#%,-T7$]%51FE()] MWA&ZV]\VN]["?WK:74IMS=*ZX9_$@H220<<"#**[7A;YFY\>+CH=H;/JE(N3+"ZIY29@Z/2`"0< M,.<*4EY/LHX;XC>-M_4<3_YALH\H:D%+,C-WEW!RLAFEI"I24T$)5/`XJ*I^R%`O?DKYJ84PGE_-'(/@2GB*(QZSHO\K)S&5VLBPN M,Q;;DA6Y"+.\B8M^XCOT.-6^:`^R(K=";AOOJ3YJM`*R@`)\\<91Z]7W?WY8 M]J5NX=W[<-*[-,`/(**M;W M(-`R5#V9^QJ$PT;R#.W)P2L:FY4AR1KDKA7WOC^TG^8P".H&JK3CTP![3'G6 M_O7O:GM_^H+[M.K;VYH"^JE>HZ3DJ11D86O)?E5K45D'@9#8AJ45DC&_-Y^F MDRN;^<>04G36PV.#KSI$T&C&2";J;C7DLH1RV671!)PW,3N$OW:O/GFAIG/4 M?J\#&4WCOJ%J*6TO9Z9@ M'``IQ)&)E+F\GB%FOE5E!3(,%RDXP$X_6*E2,6SB)V%N36UTG(2$L@NY%6JJ MAW/1"'1(F#E0QSIBHH!"[&*<`NT.U#ATO(`2/;B.1P]\;#V7N'>U\IGF=W6M M-#7MD@%*BI,N8)&.'&(-&C'_"4DP<,D5"NQ5,;V3B394NJ3-6EUXL'!//Z^:IBOJ:I$&H$IFBKQJKPWU7RI6NHNX0K\ZHQ(;\O5*0GQXQ$+SWQ-XIK/C3)/+'B]R4I.+^0$` MY>VR`A\69!4CPM]Z;R>ZS`M`$Z,[6)26=B\6$!Q"*>?K$C(8PZ M6L3?##F1PYXJ07DZO-#@>0T[C"9MM9M%IM*6-)*7-*=()4=,\209$\(2OQ`S\]COG;R,XN8(S%,9WX9TVO.;)"V-\L$C!P, M\HXB"0Z\&];D+'(.'KARZ8N#,P2:2`-!7(D4P&,:SHG5HU,I,V1QYYN.P64DMNE9*$XB0`.>)T^.>45-_,/A3_`#R4\MJ&W8&CHF3 MRB^R3741()4S0.3VC6[-5$1V+W(@\EW"8#U`!3$-QVU]%NU%W_6-DT#TI*I4 M],CVE,5-_6Q5MW75),RA,8,G(>4 M6`_Z?[R3&X8\ESX9R7-F9<=^2DI#5N?>/78(Q./,HG,6/IN0!*J51-FPE`.$ M3*&`0(")VZQ^C?8=&=Z]B*W':CN&B&JXT#4RG^9L$JD/&9)C;G:O=9L]P3:' MI"DJ'9DG@9`3PY2]V$3U>3RTR?`KR(X[YJ5-FJI%YOP?D;'EG;LP3336N,-5 ME:\P=F/L!3*"9W!O#'$V_:R$0WZ;$U871NFX*2=;P*0.*2D9^W[I1A7?2I? M[5=SV>XUL9+M)<+<\T=/%U32D)/O(,=)_DE?-O`K8%G[%<H*PD`/)(A-N%CZ_>3KE3/YG>I+1J/&[A3%XLJ$BY6[B)YCL6/ M)FFQDZ5P!/;(JO8I25E2&W*JG[")]@Z:KT2WZNI41AI01[92C'.W-17=X]X+ MW;4-`4MHLAHP$YJJ")(4G+V\H>WX9.3>#\*<;I;BMFBVU#"6=,)Y)OK>[5+( M4TRILA+A+S0N4;`T7L;QD24,!EP:G$IS;)(IF+N0Q1U4M`6RRIER0<#JCCR/ M&-F]@-V6';NVU[)W74IH-S4=54%;=1Z04J4F2@H^DSEEGRA/>=.5*'S1\@'! MS#_&:9AL/7=9;2<0[,_P#*K^^/&[GU]O[@;^L=IVNI-2[;4NNO.L@]-#00 M0J:L,-13@)YQ%!B7#7+26X&YPS%AG*EV=X#:<@;DRY"<<:6J6N3]FI<.$&>= MMD996[)Y*NT5(%Z1%^Q,8B2;=$JPIK%*<@V].Q*E?5.0ZGV'&-*67;&^3L:Z M7_;=W::ZH_J@ZD`$SU9XCB1@>$2#>5/D[QTR]X]N25 M7Q3G'%62+,C6Z=)N("D7BO6291C6N0*FDN^4CXM\X=$:(JJ$*8PE`I3'`!$! M$-3U-0D4VD'R]IC9/>C>>U]R]I+E1V*XT]4\$-DA*B)`%!,A+PG+C'"XZ>0+ MAU@CQK813ON<\:.;+5^.$"2>,XZR1D[=7D^%96;A5S5:.6=OT7[IP<&Y_D) MIH)@<14.4H".KANH0JA5JQ&D^?$2B.V.ZNS-O]JZ)JIN+*KLU;9!A)*UE0UX M`2E,X9PPC'(7?C5X"R/*'6GQ%6CN+J>6K!7:XP23:J$(9L MA+1+)ZX('84#-E"J```8-63'G]"7 M`0J50D-C2,<3IF/'C'49QP9-<;?';XO^75,:JL[OQDL=1NUK69IJ(K/:WF.Q M$MK]N[*!`W*,FL1N<3@`=CT_4=PTJG'A2,5?%/WXQ9;GL;FS^UFS^X-(VA== M:'4J60#.2RE0.7#1QA3N)=2>KHH@W,)D5DFL=#-E`;B;=S\DH=3&WBPV7W''R,7$88_5[I1D7;^W+[E4N\N MXM8I3C->TY3,)5/T-(25A(GX&0B,>M7AAXT]QV5LUBLK:BWBEKJME=2E12:<)4UHY$D@'$2^$\XDAY\QF/6W M!#DD-'\BU[YKO5C8<*ZJ%KR30;RVI:/^)[`4;&T;TY@P=L%I8Q1:>XY,=(X) M[%#?TO:E39H70MXN-Z1,<_4(VEW&=L`[87HT>Z:N_/3:F''%*#?YR)X%1!EE MY0^QMY#.&F'/'M06=HS?C>R6IAQ@K-*'&%=L4;9+=*VI;%C2&4JKB`CCO%V* MH2*@HN3/"I-T?N[S;]H#>(N="JAZ(RTY2^GOC9-L[I=O+5VDIJ1-RIG;HC;S M=/T4`]0K4VA&F4N!SB"['^*,AXS/X7*]=XY_69ZZY;R1=H:(D47#:1KU=N^3 M:0>N^^S=%]]DJ9(A9`J9P*4I%BB8NXB`6'R^+9&`G,>`QE..=Z6RW3;[>QA5 MI4Q5..U/2$L4IJ'7RA1'":5@^1QB43PW9FQAQB4Y)<..0%FKV,.04#R`M5C< M$ODDSK:V0XEZR81K*1C9636:LY%V4['Y!$@4_BM7J:B(&`Q@+Z=N'12ILX*" MSGY#^$;L["7ZU;1KKYLG<[B+?>_U5QZ:U:.JA3:/5,B68(SX>\S5T]('BE,_BSQQPRCE=_9?NUR9D6&48>4A7LK(.4F;99A:O=8@!C]QU"@&WKM&IJ4IJD'+#Z?7 M&9W+>FWJ[N_MC>-8ZRPQ4VF;BECX3-.<@<9ZIW[_Q?XG9OW=GW>G77L?,?E]6?A'2/^X_;W]/ M^<_4K?\`)ZM.K\/EE.#YC,4/R`E,9U1]FBOL2QD+DEQ&=]JCHXK M1VP*S;2/N!VH%9/UD@`2CL100U+TV^KUY?FRE/PY1SUNX9OF#M%)RS?-':1D'31VV6*=%PV M<(F$BB9@$IR&$!`0'50J)SCTULM.I*'TI<0H$$+`4"#F)*G#*`\97`4MP;WH MG%7#I+$T4]Y!0E81)$$6!0BI5AK15@KBBA#I%$HF:#V[;!TU:FCIE+ZBDS7Y MG[)QKQ':+MNU/DV\>S*(@D@54$DP,(%*`".J[Z$U*0AX`@"7 M+[(]:_=OMD[F4A5\M=$^IM.E!+2!I&&"9##(0H&(N/F%>/M<5J^$\:4[&<"L MV/ M3L&U-M[8;^7V_0TU&UQ#2$HG+*9`!/MBE3_5O682?=N/:AL&X%Z=;?MUNZEVRX;><6"\AP/ M)'^'`_3QC27>VW%NJI[DR)*<]*SCB!AAP'"*G'^W]OXZZ8"M8U\\??&B,H-Q M]-QV_N@(@`B.WKVB`B/3I^&K6K27$=,9*P/(@\"(N*=U5.KK(,EIQ!XQ>7\) M?,S!ODDPQ5N"G.:JU/*>:N/+`TQB*0R(B$HOD?'\:P)&%?MEW"B:[J[T>,.1 MF_\`O,9[&^RX$!,1?MXH[R[!5M^Z*O%`T?TAT@N)S`63@1_*"<3*6.&4;]VG M4[<[B6QFQ;K:15/4TU,ZB1+"9R.)'(Q:_7IM8MI.=95*++')RSYDW%FT=/C M=ZIUU&C4XII[FV(41`/74$)2V26P`59RBPV_M/;NUF5,[>I6Z5MQ6I00):CS M/,XQT&7N'G%S/\BWF$97B MKCI@S!L&YKF'<6T7&L.^(8DBUJ%HEHH&@+YA(P]F489" M^./@Q76]A:P?&'$<6WM<&I6K&DUK9"!+P*KUE)J13H1<&,+09&.;K[%$H@JB M0V_35)=)3.2"T"0\Q'GL=L.WE,P_3,V:WABI$G!T4'5A+,B8RX2CFU'QY$* M)-M[)5.,&&8R<:"4S224ID;)K-E"']PJR!)<'Z*3@IO10"@A]*-(/10J2<Q,`=0RTH>@=`U%YIM]OI.B;?*,EO. MW[)N&@3;+U2LU%`@I*4*2"D%/PR$L)>$=A:L-XOO&.'&'K=2J[8,7N85A775 M$DHY):MK0<8#4(N,,P$0(#6/^"E[(`("G[9=AZ:G*4EOI$?E@2EY14J[)9ZZ MVFSU=,PY:U)`+10G1(8``2D/9'&QSA#%.(:*EC'&%)KU%QZB65*E4*ZQ38PA M/UQ59:9-\8IC"<\FJN-&)W%-KLQ+3\+73UQ((YA-3S=HTF9-), MBQ3F=R;6/036,8QN\B)`'H4-2=!C0ELH04)G($3E.4\_*,9J.V6PJNA;MM5: MZ9RA:=+B4*3,!:LU&><_&<;<3XZN#\%`VZL0W&;$T=`7QI$,+C%-ZZ4&E@90 M$F6:A6T@0SDPF2BY4H.$0*)>Q7J'UU'HLZ=&A&D$")F>V>P*>B?M]/:*%NC MJ3-Q*6DIU2,\2!//E'+I7CWX0X\FF]FIO%["T--LU4'#*5"CQ<@]8N&QA,BY M9*2J;X&CDAS"/N)E*<1]1';4B::G0=2$)!\HDHNUW;JWK#E'9;B@GT MR(Q()PD.,*W?>.V$,I7''N0<@XUJ]LNV)WHR.-;1,L1<2U+??*:O@=02_N$! MFM\QBBH`[#L9,OX`&JQ2DDD@3,9#<=N6.[5E/7W"F;FY!VU6<)=1T MG,6^49._2T]32+H*A(71+:Z90<4Z)$:0,A@>&,-BM'CXX3W)G5(^S\:,2S,? M1:^6J4^.6K#9!A7:Z#YS*?I,8R:&0:H-323Q9<_V"8ZRISF$1,(ZM545*M6I M:`5>WZHPVK[9["KTL)K;72.BF:+;>I`.E!EAXY9G&,<__F;P$^'^G_Y4,/\` MP_G?J7Q_Y='L^?\`%^%\O_Y'=[WQ/X>^_P"3IZ:K=-&G1(:.44_]K.W7R/Z; M^CT/R,O@Z8EE*?G+CG#YM3QGT&D(-(0:0C0?V>N@$\(B,\8@+_J0N._^-WC6 MNUTCH\KVR<<[;6.Y4(`@':U`P^@:VEV M?OQL>^:8.`EFH!;7(YS&!QY&4:[[G6@W';2W!+J4Y"_,<9>.6>$>;MMMTW*. MW3'EPCD'4A7JG*?"1PC7;IT]=_71<=S["SU.S1ZA07C)2.4%0GNI& M$47L>[3$R#ILJ!D7#=0Z9PV-N'E72R6Z_6]VVWA`6, M>K8+NY8JL5C!5U@<)GAXK/);C?R-\>(^\1IXRN9FI23&!SCC))ZB= MS6+4+<"A.PZ)E/ENZ1:3I'6C7(EVW`Z!A]Q(=^`=^;'N6RKNY2.D.4+AFTXD M*TJ'*9`Q&$Y^<=>[-W51[GMJ7T$H<0)*0J4SXB7/ZCA$I']O[;=-81YQF<&D M(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA M&@[[=/741G$BYZ?3G,?;"&.D8A^ MK7.3#160BTG"B<>]7:*\>#J-%G;(I%#)&$3)F-VB(B&OHE07*\?(LA^W5W6Z M2-4G*64](GF[.4\IQQ-5VZU&J<+-P8#6M4IMOSE,\FHXO^$]&'_]FL$!_P#2 MC]P;,TE/^_P&1I^R MX/K]1A(5X<=H]R\=I*)28)&:]RH=AM;=T:RP5.V^EN2DJJ=I7]!973J4D^`; M<4HXRR!C8FQ:*XM7=+EFK6W99I"'0#[5-@?7'I:U-]/2=9@)&TP2=8LC^&CG M<]7$I5"<3@)==JBI(1" -----END PRIVACY-ENHANCED MESSAGE-----